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ABSTRACT OF CAPSTONE 
ENHANCING THE VALUE CARE OF LUNG CANCER TREATMENT 
FOR MEDICALLY UNDERSERVED POPULATION IN KENTUCKY 
 
Background 
For many years Kentucky has had the nation’s highest lung cancer 
incidence. Kentucky is one of the thirteen states in Appalachia in which the 
difference in wealth is a key determinant of health, since residents of Appalachia 
do not have access to the same financial resources as the rest of the US 
population. The disparities in lung cancer mortality within the Commonwealth of 
Kentucky are not completely clear, but some postulate that poor access to care or 
substandard care may contribute. In this study the value of lung cancer treatment 
for a medically underserved population (Appalachia) will be evaluated based on 
health insurance type and treatment pattern. This study will also identify factors 
which have an effect on lung cancer treatment as well as factors that determine 
the benefits of lung cancer survival and the mortality risk. 
Methodology 
Data for lung cancer cases diagnosed between 2000 and 2011 were 
obtained from the Kentucky Cancer Registry (KCR). The cohort included 49,512 
patients who met the following inclusion criteria: Lung cancer was their first 
diagnosed cancer Stage 0 through IV. Patients were classified into two distinct 
groups based on county location: Appalachian and Non-Appalachian. Chi-square, 
Cox survival regression analysis, and Kaplan Meier survival trend were performed 
to identify variables affecting treatment and survival. 
Result 
The analysis evaluated 49,512 patients from KCR. For all population, sex 
(p<.0001), age group (p<.0001), Stage (p<.0001), insurance type (p<.0001) and 
county (p<.0001) were significantly associated with the type of treatment. 
Variables such as sex, race, age, Stage, treatment, insurance, and tobacco were 
significantly associated with survival in Non-Appalachia, while the Appalachia 
variable race was not significant for affecting survival. Median survival time was 
higher for the private insurance population both in Non-Appalachia and Appalachia 
regions. 
Conclusions 
Even though the strongest predictors for survival in lung cancer are age and 
cancer Stage, health insurance does have a significant impact on improving 
survival. Health insurance provides access to recommended treatment. The 
medically underserved population received standard lung cancer treatment 
covered by the Medicaid and Medicare health plans. Over all, early diagnosis and 
timely follow up are imperative for improving value care in lung cancer treatment.  
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CHAPTER 1 
INTRODUCTION 
 
Lung cancer is the leading cause of cancer deaths in both men and women 
in the United States and causes more deaths than any other malignancy [1-3]. In 
2011, 14% of all cancer diagnosis and 27% of all cancer deaths were due to lung 
cancer [4]. With approximately 965,446 new lung cancer cases occurring per year 
among males and 386,875 cases per year among females, globally lung cancer is 
the most common cancer and the leading cause of cancer-related mortality 
accounting for 1,179,074 cancer deaths per year [5]. Unfortunately, the long term 
survival rate in the USA is less or equal to 15% of the patients surviving 5- years 
after initial diagnosis [6, 7]. Despite the development of various therapeutic 
modalities and improvement in treatment, the prognosis of lung cancer still largely 
depends on early detection at limited Stage and the immediate initiation of 
appropriate treatment [7-9]. 
The cost of all cancer care in US for 2020 is estimated to be $207 billion or 
66% increase from 2010, as the result of 5% escalating cost in the initial phases 
of care during the follow up year [10]. Economic hardship occurred not only among 
those ineligible for government financial support, but also among those receiving 
subsidies that were insufficient to meet the cost of managing a long-term illness 
over and above necessary daily living expenses [11].  Due to concerns regarding 
the financial burden to patients  more than one third of physicians surveyed had to 
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delay the start of treatment and make difficult choices about which patients to 
exclude from treatment [12]. The majority of oncologists face treatment resources  
shortages that compromise the delivery of the standard of cancer care, leading to 
higher cost; furthermore, prices charged by manufacturers and the technology 
availability are now endogenous and influenced by the design of insurance 
products and payer strategies [12, 13]. 
It is state in the previous study that patients with lung cancer mostly have 
Medicaid or were uninsured as their health insurance type [14]. Concern has been 
raised over the disproportionate cancer mortality rate among minority and low-
income persons in that the lung cancer rate is 4.5 times higher among the Medicaid 
recipients [15]. Other studies have found a discrepancy in lung cancer survival in 
relation to the availability of insurance coverage with a 3 year relative survival of 
23 % versus 13 % for the uninsured, concluding that disparities in cancer care and 
access to care were instrumental in this inequality [2]. The use of chemotherapy 
was far from consistent for all beneficiaries: the very poor received less treatment 
than would otherwise be expected while the rich received more[16]. The availability 
and access to health care may indeed be more important in determining the clinical 
outcome than previously thought [2]. Loss of insurance may therefore jeopardize 
completion of planned therapies and the management of symptoms related to 
cancer and its treatment as well as palliative care at the end of life [17]. 
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A. PROBLEM STATEMENT   
 
Cancer is a common cause of morbidity and mortality among elderly 
individuals with less robust health insurance coverage and therefore may lead to 
increased health care utilization and out of pocket expenditures [18]. Disparities in 
cancer survival is apparent between individuals enrolled in Medicaid and those not 
enrolled in Medicaid [19]. Although lung cancer is associated with a poor 
prognosis, several recommended treatment strategies exist that can result in cure 
or at least a marginally prolonged survival as well as symptomatic improvement 
for patients coping with this disease [20]. In the 21% of Medicare patients with 
Stage IV Non-Small Cell Lung Cancer (NSCLC) receiving chemotherapy for its 
treatment,   the number of individuals receiving chemotherapy is increasing relative 
to the rates that have been reported in previous studies[16]. In addition the time to 
treatment program  which is from the onset of lung cancer-related symptoms until 
diagnosis was effective in shortening the time from suspicion of lung cancer to 
diagnosis and in reducing the time intervals at each step in the process [21]. 
Arguably, more timely care in patients with lung cancer may be associated with the 
use of fewer resources and lower cost [22]. Chemotherapy prolongs survival in 
community, but it is underutilized for persons in the advanced Stage of the disease 
[23]. However, even among those with early-Stage tumors, only a fraction undergo 
surgery, due to impaired lung function or comorbid illnesses that prelude surgery 
[24]. As in many diseases, socially disadvantaged individuals who develop lung 
cancer face greater mortality risks than those who are advantaged [1].  
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In United States, cigarette smoking is linked to about 90% of lung cancer[4]. 
Kentucky and West Virginia are ranked among the top 5 states for high prevalence 
rates of adult smoking and per capita cigarette consumption [25]. Another study 
found that a higher lung cancer incidence and mortality in Appalachia that may 
result from higher smoking rates and that may correlate with the poor 
socioeconomic conditions characteristic of  the region such as limited access to 
health care [26].  In Kentucky almost half of all lung cancers are diagnosed at a 
late Stage, where only 2.5% of patients will survive 5 years or more. In addition, 
mortality data also depicts the unfavorable outcome for lung cancer [27]. Kentucky 
is a relatively poor state, with a 2011 per capita income of approximately $32.376 
(ranking forty-seventh out of the fifty states) [28]. 
Despite advancements in surgery, radiation oncology, medical oncology, 
and supportive therapies; no significant improvement in survival has been noted 
until this millennium [29]. Reliable quality measures can help distinguish high-value 
care from in expensive, but low-value, care [30].A system that is accessible to all 
patients and uses new payment models to align reimbursement to reward patients, 
high quality care, and eliminate wasteful interventions is required [31]. To achieve 
the best results, a multimodality approach is required for all lung cancer patients 
with reduction in cost while delivering similar or better clinical benefit [29, 30]. 
Therefore, does lung cancer management in Kentucky deliver high value care as 
expected for the medically underserve? 
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B. PURPOSE OF THE DISSERTATION  
 
Cancer care is an important example of the current difficulties in treatment 
due to the complexity of the disease and its treatment [31]. Cancer patients had a 
rate of bankruptcy that was 2.65 times higher than people without cancer [32]. In 
US health care utilization of metastatic lung cancer in one year follow up is $. 
125.849 per patient which include inpatient and outpatient care [33].  Kentucky’s 
poor health status results in a large, but difficult to quantify, burden of disease [28]. 
For many years Kentucky has had the nation’s highest lung cancer incidence for 
92.4/100.00 incidence rate and 68.8/100.000 mortality rate [34]. Kentucky is one 
of the thirteen states in Appalachia in which  the difference in wealth is a key 
determinant of health, since  residents of Appalachia do not have access to the 
same financial resources as the rest of the US [28]. 
Although many lung cancer management and treatment studies have been 
conducted in the past, evaluation of the value of lung cancer management for 
medically underserved populations specifically in Appalachian Kentucky have not 
been carried out. Uninsured and Medicaid-insured patients are significantly more 
likely to present with advanced-Stage cancer compared to privately insured 
patients [14]. In this study the value of lung cancer treatment for a medically 
underserved population will be evaluated based on health insurance type and 
treatment pattern. Medicaid recipients may have more comorbid conditions than 
the non-Medicaid population, and thus have lower survival rates [19]. This study 
will also identify factors which have an effect on lung cancer treatment as well as 
factors that determine the benefits of lung cancer survival and the mortality risk. 
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The purpose of this study is to provide insight as to the value of lung cancer 
management in relationship to the Affordable Care Act. Lung cancer was selected 
due to the high prevalence rate and risk of mortality for lung cancer in Kentucky. 
In addition, the diversity in the socioeconomic profile of the Commonwealth of 
Kentucky may be utilized for comparing cancer treatments. 
 
C. RESEARCH QUESTIONS  
 
This study specifically seeks to answer for the following questions: 
1. Does the type of health insurance influence the modality of lung cancer 
treatment and survival benefit for medically underserved patients? 
2. Does the lung cancer treatment for a medically underserved population in 
Kentucky reflect disparities? 
 
    D. SCOPE AND SIGNIFICANCE OF THE DISSERTATION  
 
The findings of the dissertation will contribute to the literature on lung 
cancer management, value care for lung cancer treatment and evidence based 
policy allowing the development of improved health insurance schemes for 
medically underserves populations. The Affordable Care Act provides for the 
delivery of high value care for cancer treatment and this study will provide data 
to support such efforts. It will support additional research and fill gaps in health 
service and health management in relation to cancer management. The study 
will produce an analysis of different factors that influence the value of care and 
outcome of lung cancer treatment in Kentucky. It is important to demonstrate 
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the evolution and progress of lung cancer treatment as a part of The Patient 
Protection and Affordable Care Act of 2010 (ACA). In addition, a comparison 
of outcomes between Appalachian and Non-Appalachian individuals should 
consider several disparities; for example, disparities in the Stage of diagnosis, 
disparities in health insurance type, and disparities in treatment.  
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CHAPTER 2 
LITERATURE REVIEW 
 The following review of the literature is a summary of key concepts 
foundational to understanding value care which define as  the framework for 
performance improvement in health care that depends on results not inputs [35], 
lung cancer treatment, and disparities between medically underserved populations 
in Kentucky. It represents theoretical and empirical data gathered from the 
disciplines of health care management, health care policy, and health economics. 
The works cited are collected from books, book chapters, published journal 
articles, health articles, reports, and websites. The databases and sources utilized 
to identify the scholarly literature in these areas included PubMed, Medscape, IOM 
website, ARC.gov website, CMS website, CDC website; as well as conference 
proceedings, papers, reports, bibliographies, and reference lists. The key words 
and phrases for the searches include lung cancer treatment, lung cancer cost, and 
lung cancer in Kentucky, lung cancer disparities, and value care in cancer 
treatment. A secondary review of writings referenced in the bibliographies of key 
works and those recommended by experts, peers, and colleagues augmented the 
process.  
The first portion of the chapter summarizes the major reviews and meta-
analyses on cancer treatment, followed by a synthesis of the literature published 
since 1996. This section concludes with a summary of the implications of the 
research for value care lung cancer treatment. The second portion of the chapter 
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describes the empirical and theoretical basis for investigating the value care of 
lung cancer treatment. Finally, the chapter concludes with a brief discussion of the 
literature supporting a relationship between value care and lung cancer treatment, 
value care and survival benefits of lung cancer patients, factors influencing value 
care of lung cancer treatment, and health disparities. These works form the means 
for health care reform to deliver affordable cancer treatment that involves 
strategies for focusing on lung cancer in Kentucky. 
A. BACKGROUND 
Lung cancer is a public health issue [36, 37]. In western countries including 
the United Stated and Canada as well as European countries, lung cancer is the 
leading cause of death when compared to all other cancers combined (prostate, 
breast and colon). It is considered the most lethal with an incidence rate increasing 
from year to year [37-40]. Lung cancer disparities still exist in the US and can be 
attributed to variations in lung cancer care, since these disparities are multifactorial 
[37]. The disparities in lung cancer mortality within the Commonwealth of Kentucky 
are not completely clear, but some postulate that poor access to care or 
substandard care may contribute [36]. Kentucky is the state with the highest 
mortality rate of lung and bronchial cancer  with a rate of 72/100.000 individuals 
for both sexes [41]. Many attributes of Appalachia affect the health of its residents 
and, specifically their cancer risk, screening, treatment and survival [42]. Lung 
cancer patients have a higher number of ER visits and inpatient hospitalization 
rates and significantly longer hospital stays [43]. The cost of lung cancer is 
substantial and Medicare pays a smaller proportion of the total cost over time [44]. 
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Hospitalization was the largest contributor to total cost, followed by outpatient visits 
[45]. It is possible that patients living in remote areas and those who are old and 
frail may not be offered treatment [40], while the most cost effective therapies tend 
to be those that are also the most effective [39]. In fact, chemotherapy remains 
underutilized while surgical utilization is increasing [45]. There is no routine 
screening recommended for lung cancer, and as a result many tumors are 
discovered at a late Stage of the disease [46]. Nevertheless, treatment options are 
the most appropriately based on every patient being judged based on their fitness 
for treatment, taking into account co-morbidities [47]. Patient-related reasons that 
might cause cancer to remain un-Staged after diagnosis include patient choice, 
financial constraints, or the lack of access to comprehensive care [48]. In Kentucky 
lung cancer patients utilizing all other types of insurance had a significantly higher 
risk of death within 3 years when compared to privately insured patients [49]. 
Patients  have  chosen less effective treatments with lower out of pocket costs [44]. 
Access to health insurance is known to influence the amount and quality of health 
care received, and thus the insurance status of cancer patients may be important 
to their survival [49]. 
When considering health care reform, giving value in health care refers to 
high quality care with low cost [50]. Hence, enhancing quality mean increasing 
reliability of delivery, a focus on processes of care delivery, including high reliability 
[35]; while control of costs is reducing unnecessary utilization, failure of delivery, 
coordination, and overtreatment [51]. Therefore value is the degree to which health 
services increase the likelihood of desired health outcomes, are consistent with 
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professional knowledge, and are delivered with the proper allocation of resources 
[52].  
B. THE THEORY/PREVIOUS RESEARCH SPECIFIC TO THE TOPIC  
Lung Cancer in Kentucky and USA 
The United States has reduced quality adjusted life-years despite additional 
spending for lung cancer of $19,000  per quality-adjusted life-year saved with the 
result being 1,120,000 excess deaths [53] . Each year more than 3800 people in 
Kentucky receive a diagnosis of lung cancer [20]. The gap between Kentucky and 
US lung cancer rates has one main explanation: tobacco smoking mainly 
cigarettes [22]. Most cases are diagnosed at an advanced Stage of cancer 
development, when the tumor has spread and is difficult or impossible to treat 
successfully [27]. Environmental exposures related to the coal-mining industry 
may contribute to the high incidence of lung cancer in southeastern Kentucky [26]. 
Counties in the southeast portion of the state generally have higher rates of 
smoking and lung cancer incidence [54]. The Appalachian Region, as defined in 
the Appalachian Regional Commission’s (ARC) authorizing legislation, is a 
205,000-square-mile region that follows the spine of the Appalachian Mountains 
from southern New York to northern Mississippi. It includes all of West Virginia and 
parts of 12 other states: Alabama, Georgia, Kentucky, Maryland, Mississippi, New 
York, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, and 
Virginia. Forty-two percent of the Region's population is rural, compared with 20 
percent of the national population [55] .Many additional characteristics of 
Appalachia affect the health of its residents and specifically their health as related 
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to cancer risk, screening, treatment, and survival [42]. The lung cancer rate for 
Appalachian men was nearly 25% higher than the rate for men living in the rest of 
the US [25]. Looking at the age-adjusted mortality rate by Kentucky counties, the 
rates are much higher within the eastern part of the state close to the Appalachian 
Mountains, compared to western Kentucky [23]. Also Kentucky’s age-adjusted 
cancer mortality rate is 10% higher than the national rate. This ranks Kentucky 
among the three areas with the highest cancer mortality rate in the nation (behind 
Louisiana and the District of Columbia) [23]. 
Treatment of lung cancer lags behind that of other major cancers. 48% of 
lung cancers were diagnosed at the late Stages whereas only 6% of female breast, 
6% of prostate and 20% of colorectal cancers were diagnosed late [27]. With a lag 
period of 20 to 30 years, patterns of lung cancer incidence follow smoking 
prevalence. Currently the most effective and important approach to reduce lung 
cancer burden worldwide is to reduce smoking rates through behavioral 
interventions and public health policy [5].  Lung cancer was responsible for 
162,460 deaths in 2006-90,380 men and 72,230 women [29]. This is more than 
the combined deaths from colon cancer (55, 170), breast cancer (40, 970), 
pancreatic cancer (32,300), prostate cancer (27,350) and ovarian cancer (15,310) 
[29]. Kentucky consistently has one of the highest prevalence rates of smoking 
among adults and youth in the US, leading to lung cancer rates that are 
consistently higher than seen nationally [22]. Kentucky’s age adjusted incidence 
rate of lung cancer is estimated to be the third highest in the US (behind New 
Jersey and Rhode Island) [23]. 
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Lung Cancer Treatment Disparities. 
According to Surveillance Epidemiology and End Result (SEER) data, 30% 
of Kentuckians with Lung cancer do not receive any documented surgery, radiation 
or chemotherapy [23]. Factors independently associated with higher lung cancer 
specific mortality risk include lung cancer diagnosis, late Stage disease, older age, 
male sex, white race, a higher comorbidity score, and lower median household 
income [37]. Possible reasons for the survival disparities include the fact that poor 
patients frequently have a higher levels of comorbidity when compared with more 
affluent individuals, which may make a particular cancer more difficult to treat and 
may lead to increased death from unrelated causes [49]. Within the US health care 
system, intervals between suspicion, diagnosis, and treatment of lung cancer vary 
widely and are predominantly associated with system variables such as insurance 
and hospital type. Therefore, for lung cancer and other malignancies the degree 
to which such differences reflect individual versus institutional factors remain 
unclear [56]. Lung cancer treatment patterns vary significantly among elderly 
patients in the US, despite the availability of different treatment options, many 
patients do not receive any treatment [37]. Previous studies show the decline in 
use of recommended therapy with increasing age of diagnosis, after adjustment 
for other factors including comorbidities and socioeconomic status [20]. The 
resulting disparities in receipt of guideline-concordant lung cancer care partly 
explain the disproportionate burden of  this disease among the elderly [37]. 
Patients with lung cancer with Medicaid insurance had poorer outcomes, 
including higher incidence rates, later Stage at diagnosis, and poorer survival even 
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after adjustment for Stage of diagnosis [57]. The main factor determining timely 
post-primary care referral diagnosis and treatment for lung cancer was how sick 
patient appeared [9]. An estimated 16 % of all Americans do not have health 
insurance, and in some states up to 25% of people younger than 65 years do not 
[49]. Patients with low social economic status (SES) may face other barriers that 
prevent them from seeking health care in a timely fashion, including the financial 
constraints of traveling and loss of wages [58]. Patient who appeared ill were 
referred, diagnosed, and treated more quickly and those who were sicker quicker, 
canceling out system socioeconomic inequalities that might result in longer time 
intervals for more economically deprived patients [59]. Despite the homogeneity of 
medical care, socioeconomic status was demonstrated to be a principal 
determinant of whether or not a patient received Stage specific “standard” 
treatment [60]. Disparities in outcome by race and SES persist in lung cancer 
treatment. To narrow the SES disparities, earlier diagnosis of lung cancer in 
economically impoverished patients must be made, and attention must also be 
focused on social, economic and public health issues in association with poverty 
that are also amenable to charge [58].There is a growing body of evidence that 
social disparities permeate lung cancer treatment [61]. To what extent cancer 
treatment and outcome disparities reflect individual or institutional factors remains 
unclear; furthermore in lung cancer, a number of studies have suggested that 
individual behaviors may impact treatment selection [60]. 
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Cancer Management 
Although the association between the timing of lung cancer care and 
conventional clinical endpoints, such as disease Stage and survival, remain 
unclear, prolonged intervals between suspicion, diagnosis, and treatment may 
impact other performance markers, such as patient emotional wellbeing, quality of 
life, and cost of care [56]. Cost depends on the treatment phase and episodes of 
treatment failure [43].  From 2008 to 2012, Medicare chemotherapy claims for 
services performed in hospital outpatient departments increased from 1.20 million 
annually to 1.94 million annually and now account for 29.1 % of total Medicare 
chemotherapy claims volume [62]. Cancer care, in particular, contributes to a 
substantial and growing percentage of health-care expenditures [10]. Health 
insurance plan type affects the cost. Patients that had treatment failure suffered 
from higher cost [43]. Approximately 12% of active cancer patients among 
Medicare beneficiaries receive chemotherapy in a given year and the total 
healthcare costs for these beneficiaries is about three times the cost of other 
cancer patients not receiving chemotherapy [63]. The rising out of pocket costs of 
cancer care are due to rising health insurance premiums and deductibles, as well 
as copayments for treatments [64].Treatment strategies that delay or even prevent 
disease progression could limit the cost of treatment [65].  
Those with public insurance had significantly higher expenditures for 
prescription drugs but lower expenditures for ambulatory care and other services, 
and uninsured individuals had significantly higher expenditures for ambulatory 
care and hospitalization [66]. Since hospital days are costly with optimal 
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intervention they may be reduced [67]. Supportive or palliative care can be 
provided alone as the main focus or in combination with life-prolonging therapy 
[46]. It has been estimated that the US Medicare system incurred $2 billion in total 
direct costs for lung cancer and annual direct costs of $ 1.7 billion [45]. Providers 
who were more generously reimbursed prescribed more costly chemotherapy 
regimens for metastatic breast, colorectal and lung cancer [68]. Although patients 
receiving no cancer directed treatment tended to be older and had a higher 
comorbidity burden, the variation in survival rates highlights an unmet medical 
need in this population [45]. For each advance in treatment, the increase in the 
cost of treatment exceeded the improvement in efficacy, thus making each 
treatment advance less cost effective than the one that preceded it. Medicare has 
not implemented prospective payment for cancer care that covers the course of an 
episode of illness [69]. Early diagnosis and treatment of cancer is thought to be 
important for improving survival [59]. 
Enhancing value care 
Achieving high value for patients should become the overarching goal for 
health care delivery, with value defined as the health outcomes achieved per dollar 
spent [70]. This goal is important for patients and unites the interest of all players 
in the system; if value improves, patients, payers, providers, and suppliers can all 
benefit while the economic sustainability of the health care system is improved 
[35]. Contemporary health care in the US is a complex system encompassing 
significant patient, provider, and institutional diversity [56] . Individuals in the US 
without private medical insurance are less likely to have access to medical care or 
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participate in a cancer screening program than those with private health insurance 
[14]. The lack of universal enrollment  with respect to cancer appears to be 
inconsistent with a national agenda to reduce disparities in cancer outcomes since 
it limits access to screening and follow up care to otherwise uninsured individuals 
who are not disabled or associated with another qualifying program [19]. Overall 
costs for lung cancer treatment from diagnosis to death or a  maximum of 2 years 
were $ 45.879 per patient with radiotherapy being the most costly cancer treatment 
responsible for 13% of total cost [65]. The monthly chemotherapy cost for lung 
cancer patients is more than $.3.600 [68].  
Underutilization of lung cancer diagnosis and management services among 
Medicare beneficiaries is also a cause for concern, as these service are covered 
under the Medicare program [37]. Cost reductions in the ACA are necessary and 
prudent, but if other initiatives to cut spending are taken too far or too fast, they 
become risky [51]. A greater supply of specialty providers and more hospitals in 
the beneficiaries’ county of residence may increase access for recommended care 
and reduce the time to receive that care [71]. The health care burden among those 
with cancer may be greater than the cost of cancer treatment [33]. Value care 
consisting of curative, supportive and palliative treatment should be affordable, 
effective and efficient , and reduce the greater financial risk for patients and reduce 
the waste of scarce resources [47]. Although many of the concerns facing cancer 
care delivery are found in the management of other disease that effect the elderly, 
cancer care is an important example of the challenges caused by the complexity 
of the disease and its treatment [31]. 
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C. Literature Summary and Conclusion. 
Delivering affordable cancer care has been a major goal in the US health 
care system [31, 51, 64]. Issues involving high value care,  health services that 
have high quality treatment but low cost, are important [35, 70]. Among the chronic 
diseases, cancer care has been plagued by a number of problems due to its costly 
treatment and time consuming diagnosis [23, 30, 66, 69]. Furthermore, cancer 
treatment often puts cancer patients in the unfortunate situation of losing their 
quality of life and leading to bankruptcy [9, 32, 59]. In the present study, the role of 
value care of Lung cancer treatment is investigated for a medically underserved 
population in Kentucky. Several things are thought to be correlated with value care 
of Lung cancer treatment, including health insurance and treatment patterns [37, 
49, 57, 60]. Lung cancer is the leading cause of death in both men and women in 
the US and causes more deaths than any other malignancy [1-3]. Factors 
independently associated with a higher lung cancer specific mortality risk includes 
the diagnosis, the Stage of the disease, older age, male gender, white race, higher 
comorbidities, and lower median household income [37]. The progression of 
various therapeutic modalities and improvements in treatment result the improved 
prognosis for lung cancer, which largely depends on early detection and immediate 
initiation of appropriate treatment [7-9]. 
 It is hypothesized that the type of health insurance influences the modality 
of lung cancer treatment and survival benefits for medically underserved patients. 
The following literature reviews attempt to demonstrate and support this 
hypothesis. There is a growing body of evidence that social disparities are found 
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in lung cancer treatment [61]. Patients with lung cancer with Medicaid insurance 
have poorer outcomes, including higher incidence rates, a more advanced Stage 
at diagnosis and poorer survival rate even after adjustment for Stage of diagnosis 
[57]. The resulting disparities in receipt of guideline-concordant lung cancer care 
partly explain the disproportionate burden of this disease among the elderly[37]. 
The cost of lung cancer is substantial and Medicare pays a smaller proportion of 
the total cost over time [44]. In addition, underutilization of lung cancer diagnosis 
and management services among Medicare beneficiaries is also a cause for 
concern, as these services are covered by the Medicare program[37]. 
Chemotherapy remains underutilized while surgical utilization is increasing; 
therefore, although patients receiving no cancer directed treatment tend to be older 
with higher comorbidities resulting in a large variation in survival rates. For lung 
cancer and other malignancies the degree to which such differences reflect 
individual versus institutional factors remain unclear [56]. Disparities in the Stage 
at diagnosis of lung cancer have not been thoroughly evaluated in Appalachian 
areas [42]. Uninsured patients may be diagnosed with later Stages of lung cancer 
and have an increased hazard of death [19, 72, 73]. A  Kentucky Cancer Registry 
study demonstrated that patients with lung cancer without private health insurance 
were more likely to die within 3 years of diagnosis after adjusting for the Stage at 
diagnosis [49]. Individuals without private medical insurance are less likely to have 
access to medical care or participate in a cancer screening program than those 
with private medical insurance. The uninsured and Medicaid insured patients were 
significantly more likely to present with advanced-Stage cancer compared with 
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privately insured patients [14]. These findings support the hypothesis that access 
to all treatment modalities in lung cancer may increase survival and reduce 
mortality risk for medically underserved patients.  
In summary, this review demonstrates that enhancing lung cancer 
treatment and determining the gaps among different factors which might influence 
the treatment outcome are important for reducing lung cancer mortality. However, 
most studies focus on the cost disparities in lung cancer treatment. Cost is a 
reasonable proxy for determining efficiency, although   the discussion often shifts 
to a discussion of health insurance type. While some studies highlight differences 
in health insurance type with the lung cancer treatment outcome, studies specific 
to a demographic group such as Appalachian and Non Appalachian people in 
Kentucky, have not been conducted. Given that Kentucky has one of the highest 
smoking rate and the highest prevalence of lung cancer in the US, this study will 
focus on determining the impact of health insurance type on lung cancer treatment 
outcomes. 
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CHAPTER 3 
METHODOLOGY 
Study Population. 
This was a retrospective analysis approved by the Institutional Review 
Board at the University of Kentucky. Data for Non-Small Lung Cancer Cell 
(NSCLC) cases diagnosed between 2000 and 2011 were obtained from the 
Kentucky Cancer Registry (KCR). The cohort included 49,512 patients who met 
the following inclusion criteria: Lung cancer was their first diagnosed cancer Stage 
0 through IV. 
The KCR is a population-based registry and has been awarded certification 
by the North American Association of Central Cancer Registries for an objective 
evaluation of completeness, accuracy and timeliness, and is part of the SEER 
program. The KCR links its database annually with the National Death Index to 
capture the most accurate survival information [36].  
Variables. 
Independent Variables. 
Patient demographic and clinical data included sex, race, age, Stage, 
treatment, insurance, county and tobacco use are the independent variables. 
Stage at diagnosis was defined as carcinoma in situ only few layers of cancer and 
has not spread beyond the lung (Stage 0); localized with less or equal to 3 cm  and 
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smaller than 5 cm, tumor has not spread beyond the lung (Stage I) ; localized with 
tumor size between 3-7 cm and has spread to lymph nodes surrounding the lung 
but not at distant organ (Stage II); regional with tumor between 3 cm or larger than 
7 cm and has spread beyond the lung and chest wall, diaphragm or lymph nodes 
that are further away from the lung such as neck (Stage III); and distant or the 
cancer cell has metastasized (Stage IV)[74]. On the basis of an assessment of the 
age distribution of the overall study population, age was classified as 40-49, 50-
59, 60-69, 70-79 and ≥ 80. In the analysis, to better segregate age effects and 
insurance status effects on the Stage at diagnosis, age 65 years is not used as a 
point of separation between ages categories because most patients aged 65-99 
years of age had Medicare coverage [14]. 
For purposes of this analysis, patients were classified into two distinct 
groups based on county location: Appalachian and Non-Appalachian. All included 
patients were required to have treatment information in order to be sub-classified 
based on initial treatment modality: No treatment, Surgery Only, Radiation Only, 
Chemotherapy Only, Surgery+Chemotherapy, Surgery+Radiation therapy, 
Surgery + Radiation +Chemotherapy, Radiation + Chemotherapy. 
Patient insurance status was determined by use of codes defined by the 
Facility Oncology Registry Data Standard (FORD) which identifies the patient’s 
primary insurance carrier at the time of initial diagnosis of treatment [14]. By use 
of this classification system, insurance status was grouped into the following 
categories:  Medicaid (as US government program for low-income or medically 
needy individuals) ; Medicare (a US government program covering 95% of 
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individuals aged 65 years or older as well as younger individuals who are 
permanently disabled); Uninsured (which includes codes for: not insured-not 
otherwise specified [NOS]; Not insured-charity write-off; i.e., no payment 
expected); and not insured-self pay); Private insurance plans, which included 
codes for: health maintenance organization, preferred provider organization, 
managed care-NOS; private insurance; Civilian Health and Medical program of the 
Uniformed Services [CHAMPUS] or TRICARE, military care, and insured-NOS. 
The health-care plans in the private insurance category were grouped together 
because these plans represent either privately purchased insurance (i.e., 
purchased by the individual, a family member, or an employer) or insurance 
provided by the military, which functions in a similar manner as private insurance 
(i.e., CHAMPUS or TRICARE). 
Dependent Variables. 
The clinical variable of primary interest are survival days and survival status. 
Survival time was defined as the number of days from the date of diagnosis to the 
date of death from 2000 until 2011. The survival analysis using lung cancer as the 
cause of mortality.  
Statistical Analysis. 
Analysis 1. Descriptive analysis. 
A descriptive analysis for patient demographic and clinical variables was 
performed. Descriptive statistics were utilized to evaluate the association between 
treatment and other covariates (sex, race, age, cancer Stage, insurance status, 
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county, tobacco). Person 𝑥2 test (chi-square test) or Fisher exact test (used when 
the expected number of occurrences in some cells was < 5) were utilized.  
Analysis 2. Cox survival regression analysis with model fit goodness. 
Univariable and Multivariable Cox survival regression analysis was 
performed to assess factors impacted survival, but only significant factors were 
included in the final multivariable model.  
Cox regression model for all population: 
λ(surv_days*surv_stat (2)) = λ0 (t) exp (β1X(sex)+β2(race)+β3(age)+ 
β4Stage)+ β5(treatment)+ β6(insurance)+ β7(county)+ β8(tobacco). 
Cox regression model for Non-Appalachia and Appalachia population: 
λ(surv_days*surv_stat (2)) = λ0 (t) exp (β1X(sex)+β2(race)+β3(age)+ 
β4(Stage)+ β5(treatment)+ β6(insurance)+ β7(tobacco). 
Analysis 3. Cox survival regression analysis interaction between 
insurance and treatment. 
Cox survival regression with interaction model between health insurance 
type, county and treatment were also performed to expand the interpretation from 
the model and coherent with research question.  
Cox regression model for interaction: 
λ(surv_days*surv_stat (2)) = λ0 (t) exp (β1X(sex)+β2(race)+β3(age)+ 
β4(Stage)+ β5(treatment)+ β6(insurance)+ β7(county)+ β8(tobacco)+ 
[βinteraction (insurance*treatment)]. 
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Analysis 4. Kaplan Meier survival analysis. 
Kaplan-Meier survival curves were estimated by each health insurance 
category, treatment and other significant variables from the final model for 
Appalachia and Non-Appalachia. Median survival time will be calculated and 
converted in years. 
All statistical tests were 2 sided with a p ≤ 0,05 utilized to identify statistical 
significance. 
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CHAPTER 4 
RESULTS 
A. Introduction. 
This section will display and narrate the results from the data analysis 
utilizing tables, graphs and diagrams. The results from the descriptive statistics 
provide information on the overall variables in terms of distribution, percentage and 
correlation between each. The Cox survival regression analysis demonstrates the 
effect of independent variables to dependent variables. The dependent variable is 
variable time (survival days and survival status), while independent variables are 
sex, race, age, Stage, treatment, insurance, county and tobacco. Also included in 
the Cox survival regression analysis is interaction between insurance and 
treatment, which expands the interpretation. Data from the Cox survival regression 
analysis is presented as a data compilation consisting of hazard ratio, 95% 
Confidence Interval, and P Value utilizing tables and graphs. The results of the 
Kaplan Meier survival trend analysis defines the median survival time for selected 
variables. Data from the Kaplan Meier survival trend analysis will be presented as 
a data compilation consisting of the median survival time in years and its 95% 
Confidence Interval with survival curves. 
B. Data Analysis. 
Analysis 1.Descriptive analysis. 
The patient cohort consisted of 49,512 eligible patients with a first diagnosis 
of Non-Small Cell Lung Cancer (NSCLC) from 2000-2011. Patient demographics 
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and clinical data are divided into two groups Non-Appalachia and Appalachia. 
Cross tab frequency with chi-square was calculated between treatment and other 
covariates. 
Non-Appalachia 
Table 1 describes the data for lung cancer treatment for Non-Appalachia.  
The sample distribution for the treatment group is 27.9% for No treatment (9374 
patients); 15.24% for Surgery Only (5106 patients); 11.8% for Radiation Only 
(3964 patients);14.7% for Surgery+Chemotherapy (4930 patients); 3.02% for 
Surgery+Radiation (1014 patients); 1.7% for Surgery+Radiation+Chemotherapy 
(570 patients); 22.4% for Radiation+Chemotherapy (7502 patients); 3% for 
chemotherapy (1007 patients) ; and 0.0008% for unknown/other therapy (28 
patients). 
The total population in Non-Appalachia is 33495 consisting of 53.7% female 
(n: 18003) and 46.25% male (n: 15492). Female and male patients were primarily 
treated with Radiation+Chemotherapy (female: 23.18%, and male: 21.49%), with 
few individuals receiving Surgery+Radiation+Chemotherapy (female: 2.92%, and 
male: 3.15%). The association between sex and treatment is statistically significant 
(p <.0001). 
Non-Appalachia has 91.9% white race (n: 30784) compare to 8% other 
races (n: 2711). White and other race was treated most often with 
Radiation+Chemotherapy (white: 22.51%, and other: 21.14%) and  were treated 
less frequently with Surgery+Radiation+Chemotherapy (white: 1.7%, and other: 
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1.77%). The association between race and treatment was not statistically 
significant (p = 0.13). 
Age group 70-79 was the largest Non-Appalachia age group at 32.1 % of the 
total (n: 10763) with only 5% in age group 40-49 (n: 1717). The four age groups 
receiving Radiation+Chemotherapy were age group 40-49: 36.92%, age group 50-
59: 32.43%, age group 60-69: 26.8%, and age group 70-79: 18.08%) and those 
receiving Surgery+Radiation+Chemotherapy least often were age group 40-49: 
1.11%, age group 50-59: 1.61%, age group 60-69: 2.05%, age group 70-79: 
1.78%. The age group ≥ 80 most received Radiation Only (17.53%) and were least 
likely to receive Chemotherapy Only (0.21%). The association between age group 
and treatment is statistically significant (p<.0001). 
Stage IV is the most frequent Stage level found in the Non-Appalachia 
population at 39.7 % (n: 13314), while Stage 0 yielded a very low number at0.001% 
(n: 35). In relation to treatment, Stage 0 did not receive the following treatments: 
Surgery+Chemotherapy, Surgery+Radiation, and 
Surgery+Radiation+Chemotherapy. Most patients at Stage 0 underwent Surgery 
Only (11.43%), fewest receiving Chemotherapy (2.86%). 
Patients with Stage I most frequently underwent Surgery Only (56.45%) and 
least frequently chemotherapy (1.98%) most frequently, while patients with Stage 
II also underwent most frequently Surgery Only (26.85%), but least often 
Surgery+Chemotherapy (5.06%). Patients with Stage III underwent 
Radiation+Chemotherapy (36.1%) most frequently and least frequently Surgery 
Only (5.44%), while patients with Stage IV underwent Radiation+Chemotherapy 
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(25.39%) most frequently and least frequently Surgery+Radiation+Chemotherapy 
(0.81%). The unknown Stage most frequently was a treated with 
Radiation+Chemotherapy (10.3%) and least often with 
Surgery+Radiation+Chemotherapy (0.73%). The association between Stage and 
treatment is statistically significant (p<.0001). 
The largest (64.3%) population in Non-Appalachia has Medicare coverage 
(n: 21541). All insurance groups most frequently received 
Radiation+Chemotherapy (uninsured: 34.45%, private insurance: 31.63%, 
Medicaid: 29.34%, Medicare: 18.89%, unknown: 6.95%) but all groups were less 
likely to receive Surgery+Radiation+Chemotherapy (uninsured: 1.25%, private 
insurance: 1.7%, Medicaid: 1.5%, Medicare: 1.81% and unknown: 0.36%). The 
correlation between insurance group and treatment is statistically significant 
(p<.0001). 
Tobacco Uses among lung cancer patients in the Non-Appalachia cohort 
was highest at 79.8% (n: 26739). All tobacco use groups most frequently received 
Radiation+Chemotherapy (never used: 21.11%, tobacco user: 22.52%, unknown: 
22.41%) and all groups were less likely to be treated with 
Surgery+Radiation+Chemotherapy (never used: 1.42%, tobacco user: 1.73%, 
unknown: 1.69%). The association between tobacco and treatment is not 
statistically significant (p=0.4%).
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Table 1. Data description for Lung Cancer by treatment for Non-Appalachia 
            
     
Treatment 
      
 
Total 1 2 3 4 5 6 7 8 9 
P-
value 
 
n:33495 n:9374 n:5106 n:3964 n:4930 n:1014 n:570 n:7502 n:1007 n:28 
 
            Variables 
           
            Sex (%) 
          
<.0001 
Female 
18003 
(100) 
4990  
(27.72) 
2514  
(13.96) 
2187  
(12.15) 
2715 
(15.08) 
526  
(2.92) 
302  
(1.68) 
4173  
(23.18) 
579  
(3.22) 
17  
(0.09) 
 
Male 
15492 
(100) 
4384    
(28.3) 
2592  
(16.73) 
1777  
(11.47) 
2215   
(14.3) 
488  
(3.15) 
268  
(1.73) 
3329  
(21.49) 
428  
(2.76) 
11  
(0.007) 
 
            Race (%) 
     
0.13 
White 
30784 
(100) 
8580  
(27.87) 
4717  
(15.32) 
3611  
(11.73) 
4522  
(14.69) 
940   
(3.05) 
522      
(1.7) 
6929  
(22.51) 
938  
(3.05) 
25  
(0.08) 
 
Other 
2711   
(100) 
794    
(29.29) 
389    
(14.35) 
353     
(13.02) 
408    
(15.05) 
74     
(2.74) 
48      
(1.77) 
573    
(21.14) 
69    
(2.55) 
3     
(0.11 
 
      
      
Age (%) 
     
     <.0001 
40-49 
1717   
(100) 
228   
(13.28) 
230      
(13.4) 
123     
(7.16) 
287  
(16.72) 
72   
(4.19) 
19    
(1.11) 
634    
(36.92) 
123  
(7.16) 
1  (0.06) 
 
50-59 
5408   
(100) 
853   
(15.77) 
823    
(15.22) 
450     
(8.32) 
901  
(16.66) 
254   
(4.7) 
87    
(1.61) 
1754  
(32.43) 
283  
(5.23) 
3  (0.06) 
60-69 
10285 
(100) 
2086 
(20.28) 
1743  
(16.95) 
1077 
(10.47) 
1648 
(16.02) 
395 
(3.84) 
211  
(2.05) 
2756    
(26.8) 
360    
(3.5) 
9  (0.09)  
70-79 
10763 
(100) 
3279 
(30.47) 
1843  
(17.12) 
1381  
(12.83) 
1614     
(15) 
269   
(2.5) 
192  
(1.78) 
1946  
(18.08) 
230  
(2.14) 
9  (0.08)  
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≥80 
5322   
(100) 
2928 
(55.02) 
467      
(8.77) 
933    
(17.53) 
480     
(9.02) 
24   
(0.45) 
61    
(1.15) 
412      
(7.74) 
11    
(0.21) 
6  (0.11) 
 
    
      
  Stage (%) 
   
      <.0001 
Stage I 
6526  
(100) 
834   
(12.78) 
3684  
(56.45) 
720   
(11.03) 
170      
(2.6) 
343    
(5.26) 
167  
(2.56) 
475      
(7.28) 
129    
(1.98) 
4   
(0.06) 
 
Stage II 
1739  
(100) 
197   
(11.33) 
467    
(26.85) 
117     
(6.73) 
88      
(5.06) 
231  
(13.28) 
130  
(7.48) 
316    
(18.17) 
192  
(11.04) 
1   
(0.06) 
 
Stage III 
8161  
(100) 
1857 
(22.75) 
444      
(5.44) 
830   
(10.17) 
1157(14.1
8) 
279  
(27.51) 
138  
(1.69) 
2946    
(36.1) 
506      
(6.2) 
4   
(0.05) 
 
Stage IV 
13314(10
0) 
4114   
(30.9) 
196      
(1.47) 
2041 
(15.33) 
3201 
(24.04) 
119    
(0.89) 
108  
(0.81) 
3380  
(25.39) 
137    
(1.03) 
18 
(0.14) 
 
Stage 0 
35      
(100) 
17     
(48.57) 
11      
(31.43) 
4        
(11.43) 0 0 
0 2           
(5.71) 
1        
(2.86) 
0  
Unknown 
3720  
(100) 
2355 
(63.31) 
304      
(8.17) 
252     
(6.77) 
314     
(8.44) 
42      
(1.13) 
27     
(0.73) 
383      
(10.3) 
42      
(1.13) 
1    
(0.03) 
 
       
     
Insurance (%) 
  
    <.0001 
uninsured 
1196  
(100) 
266   
(22.24) 
98       
(8.19) 
131   
(10.95) 
203    
(16.97) 
36      
(3.01) 
15    
(1.25) 
412    
(34.45) 
35    
(2.93) 0 
 private 
insurance 
7574  
(100) 
1021 
(13.48) 
1308 
(17.27) 
627     
(8.28) 
1278  
(16.87) 
365    
(4.82) 
134  
(1.77) 
2396  
(31.63) 
438  
(5.78) 
7   
(0.09) 
 
Medicaid 
1803  
(100) 
404    
(22.41) 
216   
(11.98) 
218   
(12.09) 
287    
(15.92) 
62      
(3.44) 
27      
(1.5) 
529    
(29.34) 
58    
(3.22) 
2   
(0.11) 
 
Medicare 
21541(10
0) 
6574  
(30.52) 
3445 
(15.99) 
2937 
(13.63) 
3096  
(14.37) 
546    
(2.53) 
389  
(1.81) 
4069  
(18.89) 
466  
(2.16) 
19 
(0.09) 
 
unknown 
1381   
(100) 
1109    
(80.3) 
39        
(2.82) 
51       
(3.69) 
66         
(4.78) 
5         
(0.36) 
5      
(0.36) 
96         
(6.95) 
10     
(0.72 
0  
   
         
Tobacco (%) 
     
     0.4 
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never used 
2610   
(100) 
732   
(28.05) 
388   
(14.87) 
342      
(13.1) 
387   
(14.83) 
85     
(3.26) 
37    
(1.42) 
551   
(21.11) 
86     
(3.3) 
2  (0.08)  
tobacco user 
26739 
(100) 
7476 
(27.96) 
4054 
(15.16) 
3139  
(11.74) 
3940 
(14.74) 
828 
(3.09) 
463  
(1.73) 
6022 
(22.52) 
795 
(2.97) 
22(0.08)  
unknown 
4146   
(100) 
1166 
(28.12) 
664   
(16.02) 
483     
(11.65) 
630   
(14.54) 
101    
(2.44) 
70    
(1.69) 
929   
(22.41) 
126 
(3.04) 
4    (0.1)  
      
     
 
 
Explanation 
 
     
 
 
1. No treatment 
 
       
 
 
2. Surgery Only 
 
       
 
 
3. Radiation Only 
 
       
 
 
4. Surgery + Chemotherapy        
 
 
5. Surgery+Radiation 
 
       
 
 
6.Surgery+Radiation+Chemothera
py 
       
 
 
7. Radiation+Chemotherapy        
 
 
8. Chemotherapy 
 
       
 
 
9.Unknown/Other therapy 
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Appalachia 
Table 2 is a description of Lung cancer in Appalachia. The sample distribution for 
treatment is 34.2% for No treatment (5482 patients); 14.7% for Surgery Only (2361 
patients); 10.6% for Radiation Only (1702 patients); 11.6% for Surgery+Chemotherapy 
(1872 patients); 2.8% for Surgery+Radiation (447 patients); 1.5% for 
Surgery+Radiation+Chemotherapy (252 patients); 21% for Radiation+Chemotherapy 
(3368 patients); 3.1% for chemotherapy (498 patients); 0.0002% for unknown/other 
therapy (35 patients). 
The total Appalachia population is 16017 with 57.7% female (n: 9253) and 42.2% 
male (n: 6764). Female and male patients received most frequently were treated with 
radiation and chemotherapy (female: 21.07% and male: 20.96%) and less likely to be 
treated with Surgery+Radiation+Chemotherapy (female: 1.63% and male: 1.49%). The 
association between sex and treatment is statistically significant (p=.0003). 
White race dominated the Appalachia population at 98.6% (n: 15800), while other 
is 1.35% (n: 2171). White race were most frequently treated with 
Radiation+Chemotherapy (female: 21.08% and male: 17.05 %) and were less likely to be 
treated with Surgery+Radiation+Chemotherapy (female: 1.59% and male: 0.46 %). The 
association between race and treatment is not statistically significant (p=0.06). 
The largest age group in Appalachia is also age group 70-79 at 67.2% (n: 10763) 
and the smallest is age group 40-49 with 10.7% (n: 1717). Four age groups receive 
Radiation+Chemotherapy most often: age group 40-49: 33.58%, age group 50-59: 
31.3%, age group 60-69: 23.84%, age group 70-79: 14.54% and are treated with 
Surgery+Radiation+Chemotherapy less frequently (age group 40-49: 1.49%, age group 
34 
 
50-59: 1.69%, age group 60-69: 1.72%, age group 70-79: 1.53%). Age group ≥80 most 
frequently receives Radiation Only (13.42%) and is less likely to receive 
Surgery+Radiation (0.33%). The association between age groups and treatment is 
statistically significant (p<.0001). 
Similar to Non-Appalachia, Stage IV is the most frequent Stage found in 
Appalachia with 39% if the total population (n: 6263) and Stage 0 also yields a very small 
number at 0.0009% (n: 16). Stage 0 in Appalachia there are no observations for 
Surgery+Chemotherapy, Surgery+Radiation, Surgery+Radiation+Chemotherapy, and 
Chemotherapy; however, there is the same percentage undergoing treatment most 
frequently with Radiation Only and Radiation+Chemotherapy (18.75%). Stage I and 
Stage II undergo most frequently Surgery Only (Stage I: 56.86% and Stage II: 32%); 
however, Stage I is treated less frequently with Surgery+Radiation+Chemotherapy 
(2.35%); while Stage II receives Surgery+Chemotherapy less frequently (4.01%). Stage 
III, Stage IV and Unknown Stage most frequently received treatment with 
Radiation+Chemotherapy (Stage III: 32.37%, Stage IV; 24.65%, unknown: 11.8%) and 
undergoing least treatment for Surgery+Radiation+Chemotherapy (Stage III: 1.82%, 
Stage IV: 1.82%, unknown: 0.6%). Association between Stage and treatment is 
statistically significant (p<.0001). 
Most (64.2%) population in Appalachia is also Medicare population (n: 10294). 
Four insurance groups get most treatment for Radiation+Chemotherapy (uninsured: 
27.72%, private insurance: 30.96%, Medicaid: 26.97%, and Medicare: 18.44%). 
Unknown Stage get most treatment for Surgery+Chemotherapy (5.73%). All insurance 
group get least treatment for Surgery+Radiation+Chemotherapy (uninsured: 1.31%, 
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private insurance: 1.8%, Medicaid: 1.87%, Medicare: 1.56%, and unknown: 0.49%). 
Association between Insurance group and treatment is statistically significant (p<.0001). 
In Appalachia the largest proportion among lung cancer patients in Tobacco Use 
group is tobacco user with 79.5% (n: 12736). All three tobacco use get most treatment 
for Radiation+Chemotherapy (never use: 21.64%, tobacco user: 20.99%, and unknown: 
20.91%). Never use group get least treatment for Chemotherapy (3.36%), while the other 
two groups get least treatment for Surgery+Radiation+Chemotherapy (tobacco use: 
1.57% and unknown: 1.75%). Association between tobacco use and treatment is not 
statistically significant (p=0.6). 
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Table 2. Data description for Lung Cancer by treatment for Appalachian 
            
     
Treatment 
      
 
Total 1 2 3 4 5 6 7 8 9 
P-
value 
 
n:16017 n:5482 n:2361 n:1702 n:1872 n:447 n:252 n:3368 n:498 n:35 
 
            Variables 
           
            Sex (%) 
          
0.0003 
Female 
9253  
(100) 
3142  
(33.96) 
1305    
(14.1) 
1059  
(11.44) 
1084  
(11.72) 
238  
(2.57) 
151  
(1.63) 
1950  
(21.07) 
307   
(3.32) 
17   
(0.18) 
 
Male 
6764  
(100) 
2340  
(34.59) 
1056  
(15.61) 
643      
(9.51) 
788    
(11.65) 
209  
(3.09) 
101  
(1.49) 
1418  
(20.96) 
191   
(2.82) 
18   
(0.27) 
 
   
  
       Race (%) 
       
0.06 
White 
15800(10
0) 
5385  
(34.08) 
2330  
(14.75) 
1678  
(10.62) 
1854  
(11.73) 
444   
(2.81) 
251   
(1.59) 
3331  
(21.08) 
492   
(3.11) 
35   
(0.22) 
 
Other 
217    
(100) 
97       
(44.7) 
31        
(1.31) 
24      
(11.06) 
18       
(8.29) 
3       
(1.38) 
1        
(0.46) 
37      
(17.05) 
6       
(2.76) 0 
 
      
   
   Age (%) 
     
   
  
<.0001 
40-49 
941    
(100) 
164    
(17.43) 
124     
(13.18) 
91      
(9.67) 
135  
(14.35) 
34     
(3.61) 
14   
(1.49) 
316   
(33.58) 
59    
(6.27) 
4   
(0.43) 
 
50-59 
3026  
(100) 
657    
(21.71) 
427     
(14.11) 
260    
(8.59) 
416  
(13.75) 
113   
(3.73) 
51   
(1.69) 
947     
(31.3) 
150  
(4.96) 
5   
(0.17) 
 
60-69 
5515  
(100) 
1578  
(28.61) 
912     
(16.54) 
536    
(9.72) 
671  
(12.17) 
196   
(3.55) 
95   
(1.72) 
1315 
(23.84) 
199  
(3.61) 
13 
(0.24) 
 
70-79 
4739  
(100) 
1912  
(40.35) 
765     
(16.14) 
574  
(12.11) 
531    
(11.2) 
98     
(2.07) 
75   
(1.58) 
689   
(14.54) 
88     
(1.86) 
7   
(0.15) 
 
≥80 
1796  
(100) 
1171    
(65.2) 
133       
(7.41) 
241  
(13.42) 
119    
(6.63) 
6        
(0.33) 
17   
(0.95) 
101     
(5.62) 
2       
(0.11) 
6   
(0.33) 
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Stage (%) 
   
    
   
<.0001 
Stage I 
2771  
(100) 
483   
(17.43) 
1548  
(55.86) 
232    
(8.37) 
76       
(2.74) 
136    
(4.91) 
65     
(2.35) 
150      
(5.41) 
79     
(2.85) 
2  
(0.07) 
 
Stage II 
822    
(100) 
111     
(13.5) 
263          
(32) 
51         
(6.2) 
33       
(4.01) 
110  
(13.38) 
61     
(7.42) 
120      
(14.6) 
73     
(8.88) 0 
 
Stage III 
4007  
(100) 
1235 
(30.82) 
258       
(6.44) 
350     
(8.73) 
421   
(10.51) 
126    
(3.14) 
73     
(1.82) 
1297  
(32.37) 
240   
(5.99) 
7  
(0.17) 
 
Stage IV 
6263  
(100) 
2309 
(36.87) 
102       
(1.63) 
926   
(14.79) 
1180 
(18.84) 
56      
(0.89) 
40     
(0.64) 
1544  
(24.65) 
83     
(1.33) 
23 
(0.37) 
 
Stage 0 
16      
(100) 
6          
(37.5) 
4               
(25) 
3       
(18.75) 
0 0 0 3         
(18.75) 
0 0 
 
Unknown 
2138  
(100) 
1338  
(62.58) 
186         
(8.7) 
140     
(6.55) 
162      
(7.58) 
19      
(0.89) 
13     
(0.61) 
254     
(11.88) 
23      
(1.08) 
3  
(8.57) 
 
    
      
  Insurance (%) 
  
      
 
<.0001 
uninsured 
534    
(100) 
142  
(26.59) 
48       
(8.99) 
63       
(11.8) 
87     
(16.29) 
20      
(3.75) 
7     
(1.31) 
148  
(27.72) 
17   
(3.18) 
2  
(0.37) 
 private 
insurance 
2500  
(100) 
433  
(17.32) 
428   
(17.12) 
216     
(8.64) 
341   
(13.64) 
110      
(4.4) 
41     
(1.8) 
774  
(30.96) 
152 
(6.08) 
1  
(0.04) 
 
Medicaid 
1869  
(100) 
530  
(28.36) 
254   
(13.59) 
170       
(9.1) 
253   
(13.54) 
42       
(2.25) 
35   
(1.87) 
504  
(26.97) 
70   
(3.75) 
11(0.59
) 
 
Medicare 
10294(10
0) 
3749(36.42
) 
1592 
(15.47) 
1212 
(11.77) 
1144 
(11.11) 
260     
(2.53) 
161 
(1.56) 
1898(18.4
4) 
257   
(2.5) 
21  
(0.2) 
 
unknown 
820    
(100) 
628  
(76.59) 
39        
(4.76) 
41             
(5) 
47       
(5.73) 
15       
(1.83) 
4     
(0.49) 
44      
(5.37) 
2      
(0.24) 0 
 
   
      
   Tobacco (%) 
  
      
  
0.6 
never used 
1220   
(100) 
408   
(33.44) 
180   
(14.75) 
119    
(9.75) 
142  
(11.64) 
47      
(3.85) 
16    
(6.35) 
264   
(21.64) 
41    
(3.36) 
3     
(0.25) 
 
tobacco user 
12736 
(100) 
4394   
(34.5) 
1875 
(14.72) 
1360(10.6
8) 
1477  
(11.6) 
343    
(2.69) 
200  
(1.57) 
2673 
(20.99) 
390  
(3.06) 
24   
(0.19) 
 
unknown 
2061   
(100) 
680   
(32.99) 
306   
(14.85) 
223   
(10.82) 
253  
(12.28) 
57      
(2.77) 
36    
(1.75) 
431   
(20.91) 
67    
(3.25) 
8     
(0.39) 
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Explanation 
 
     
   
 
1. No treatment 
 
     
   
 
2. Surgery Only 
 
     
 
3. Radiation Only 
 
        
 
4. Surgery + 
Chemotherapy 
  
   
 
   
 
5. Surgery+Radiation 
  
   
 
   
 
6.Surgery+Radiation+Chemotherapy 
 
   
 
   
 
7.Radiation+Chemothe
rapy 
  
   
 
   
 
8. Chemotherapy 
  
   
    
 
9.Unknown/Other 
therapy 
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Analysis 2. Cox Survival Regression Analysis Model Fit. 
Univariable analysis was performed to evaluate demographic and clinical factors 
for outcome in all patients including sex, race, age, Stage, treatment, county and tobacco. 
Only significant variables were included in the multivariable model.  
All population 
Table 3 is the Hazard Ratio for all populations, which is Non-Appalachia and 
Appalachia combined together. In this analysis all variables are significant (sex (p<.0001), 
race (p=0149), Stage (p<.0001), treatment (p<.0001), insurance (p<.0001), county 
(p=.03) and tobacco (p<.0001)). 
The hazard ratio (HR) observation shows that female has a 1.123 (95%CI, 1.09-
1.159) higher risk than male (p<.0001). White race has a 1.08 (95%CI, 1.016-1.161) 
higher risk than other race (p=0.0149). With respect to age group ≥ 80 was 0.67 (95%CI, 
0.62-0.73), 0.7 (95%CI, 0.66-0.75), 0.79 (95%CI, 0.75-0.83), 0.9 (95%CI, 0.85-0.95) for 
age group 40-49, 50-59, 60-69, and 70-79 respectively (p<.0001). 
The Stage gradually increased the risk of mortality and the State increased;  the 
HR estimates were 0.6(95%CI, 0.39-0.97), 0.77(95%CI, 0.72-0.82), 0.99(95%CI, 0.91-
1.08), 1.3(95%CI, 1.23-1.38), and 2.24(95%CI, 2.1-2.4) for Stage 0 (p=.036), Stage I 
(p<.0001), Stage II (p=0.8), Stage III (p<.0001), and Stage IV (p<.0001) relative to 
Unknown Stage, respectively. 
The No treatment group has a 1.4 (95%CI, 0.7-1.8) higher risk of mortality 
compared to the unknown/other therapy group (p=0.58). The rest of the treatment groups 
were 0.35 (95%CI, 0.22-0.57), 0.85 (95%CI, 0.53-1.4), 0.6 (95%CI, 0.38-0.98), 
0.35(95%ci, 0.217-0.57), 0.4 (95%CI, 0.25-0.65), 0.5 (95%CI, 0.33-0.85), and 0.35 
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(95%CI, 0.21-0.57) for Surgery Only (p<.0001), Radiation Only (p=0.52), 
Surgery+Chemotherapy (p=0.04), Surgery+Radiation (p<.0001), 
Surgery+Radiation+Chemotherapy (p=.0003), Radiation+Chemotherapy (p=.008), and 
chemotherapy (p<.0001) relative to the unknown treatment group. 
The Uninsured group has a 0.9 (95%CI, 0.8-1.016) higher risk compared to the 
Unknown Insurance group (p=0.09). With respect to the Unknown Insurance group the 
HR estimates were 0.7 (95%CI, 0.6-0.76), 0.8 (95%CI, 0.7-0.9), 0.7 (95%CI, 0.7-0.86) for 
private insurance (p<.0001), Medicaid (p=.0014), and Medicare (p<.0001), respectively. 
In term of county location Non-Appalachia is 0.96 (95%CI, 0.93-0.99) relative to 
Appalachia (p=.0289). Both Never Use and Tobacco User groups increase the risk of 
mortality with an HR estimate 1.28 (95%CI, 1.195-1.374) and 1.16 (95%CI, 1.107-1.2) 
compared to Unknown User (p<.0001), respectively. 
 
 
Table 3. Hazard Ratio for All Population 
Variable p 
Hazard 
Ratio 
95% Hazard Ratio 
Limits Reference 
Sex 
     1.Female <.0001 1.123 1.09 1.159 Male 
      Race 
     2.White 0.0149 1.086 1.016 1.161 Other 
      Age 
     1.40-49 <.0001 0.676 0.621 0.737 
 2.50-59 <.0001 0.704 0.659 0.751 ≥80 
3.60-69 <.0001 0.793 0.752 0.836 
 4.70-79 <.0001 0.9 0.857 0.946 
 
      Stage 
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1.Stage I <.0001 0.772 0.723 0.825 
 2.Stage II 0.8874 0.994 0.912 1.083 
 3.Stage III <.0001 1.306 1.23 1.386 unknown Stage 
4.Stage IV <.0001 2.246 2.122 2.377 
 5.Stage 0 0.0367 0.617 0.393 0.971 
 
      Treatment 
     1. No treatment 0.5863 1.141 0.709 1.838 
 2. Surgery Only <.0001 0.355 0.22 0.573 
 3. Radiation Only 0.5209 0.855 0.53 1.379 
 
4. Surgery + Chemotherapy 
0.0442 0.612 0.38 0.987 unknown/other 
therapy 
5. Surgery+Radiation <.0001 0.352 0.217 0.572 
 6.Surgery+Radiation+Chemo 
Therapy 
0.0003 0.404 0.247 0.659 
 7. Radiation+Chemotherapy 0.0086 0.528 0.327 0.85 
 8. Chemotherapy <.0001 0.353 0.218 0.573 
 
      Insurance 
     1.Uninsured 0.0901 0.905 0.805 1.016 
 
2.Private Insurance 
<.0001 0.703 0.643 0.769 unknown insurance 
group 
3.Medicaid 0.0014 0.849 0.768 0.939 
 4.Medicare <.0001 0.793 0.73 0.861 
 
      County 
     1.Non Appalachia 0.0289 0.963 0.931 0.996 Appalachia 
      Tobacco 
     1.Never used <.0001 1.282 1.195 1.374 unknown group 
2.Tobacco user <.0001 1.163 1.107 1.222 
  
Non-Appalachia 
Table 4 is the Hazard Ratio for Non-Appalachia. In this analysis all variables are 
significant (sex (p<.0001), race (p.0063), Stage (p<.0001), treatment (p<.0001), 
insurance (p<.0001) and tobacco (p<.0001)). 
The hazard ratio (HR) observation demonstrated that female has a 1.1 (95%CI, 
1.06-1.147) higher risk than male (p<.0001). White race has a 1.1 (95%CI, 1.028-1.182) 
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higher risk than other race (p=0.0063). With respect to age group ≥ 80 was 0.7 (95%CI, 
0.6-0.8), 0.7 (95%CI, 0.68-0.8), 0.8 (95%CI, 0.76-0.86), 0.9 (95%CI, 0.89-1) for age group 
40-49 (p<.0001), 50-59 (p<.0001), 60-69 (p<.0001), and 70-79 (p=.05) respectively. 
Obviously, Stage level gradually increase the mortality risk  with HR estimates 
were 0.5 (95%CI, 0.3-0.9), 0.75(95%CI, 0.69-0.8), 0.97(95%CI, 0.88-1.08), 1.3 (95%CI, 
1.21-1.4), and 2.2 (95%CI, 2.07-2.4) for Stage 0 (p=.02), Stage I (p<.0001), Stage II 
(p=0.68), Stage III (p<.0001), and Stage IV (p<.0001) relative to unknown Stage, 
respectively. 
No treatment group has a 1.4 (95%CI, 0.69-2.8) higher risk of mortality compared 
to Unknown/Other Therapy (p=0.3). The rest of the treatment groups were 0.4 (95%CI, 
0.2-0.85), 1.04 (95%CI, 0.5-2.1), 0.75 (95%CI, 0.37-1.5), 0.4 (95%CI, 0.2-0.8), 0.46 
(95%CI, 0.2-0.9), 0.6 (95%CI, 0.3-1.27), and 0.39 (95%CI, 0.19-0.8) for Surgery Only 
(p=.015), Radiation Only (p=0.8), Surgery+Chemotherapy (p=0.4), Surgery+Radiation 
(p=.015), Surgery+Radiation+Chemotherapy (p=.03), Radiation+Chemotherapy (p=0.2), 
and chemotherapy (p=0.01) relative to Unknown Treatment, respectively. 
The Uninsured group has a 0.89 (95%CI, 0.7-1.03) higher risk compare to the 
Unknown Insurance group (p=0.14). The HR estimates were 0.7 (95%CI, 0.6-0.78), 0.79 
(95%CI, 0.69-0.9), 0.79 (95%CI, 0.7-0.87) for Private Insurance (p<.0001), Medicaid 
(p=.0007), and Medicare (p<.0001) relative to the Unknown Insurance group. Both Never 
Use and Tobacco Use groups increased the risk of mortality with an HR estimate 1.25 
(95%CI, 1.15-1.36) and 1.13 (95%CI, 1.07-1.2) compared to Unknown User (p<.0001), 
respectively. 
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Table 4.  Hazard Ratio for Non-Appalachia county 
Variable p 
Hazard 
Ratio 
95% Hazard Ratio 
Limits 
Reference 
 
Sex 
     1.Female <.0001 1.106 1.065 1.147 Male 
      Race 
     1.White 0.0063 1.102 1.028 1.182 Other 
      Age 
     1.40-49 <.0001 0.728 0.656 0.808 
 2.50-59 <.0001 0.742 0.685 0.804 ≥80 
3.60-69 <.0001 0.812 0.762 0.864 
 4.70-79 0.0525 0.944 0.891 1.001 
 
      Stage 
     1.Stage I <.0001 0.753 0.694 0.817 
 2.Stage II 0.6877 0.978 0.88 1.088 
 3.Stage III <.0001 1.304 1.21 1.406 unknown Stage 
4.Stage IV <.0001 2.221 2.069 2.385 
 5.Stage 0 0.0236 0.531 0.307 0.919 
 
      Treatment 
     1. No treatment 0.3493 1.393 0.696 2.789 
 2. Surgery Only 0.0157 0.424 0.212 0.851 
 3. Radiation Only 0.895 1.048 0.523 2.1 
 
4. Surgery + Chemotherapy 
0.4379 0.759 0.379 1.522 unknown/other 
therapy 
5. Surgery+Radiation 0.0154 0.42 0.208 0.847 
 6. Surgery+Radiation+ Chemo 
therapy 
0.0315 0.46 0.226 0.933 
 7. Radiation+Chemotherapy 0.2019 0.636 0.318 1.274 
 8. Chemotherapy 0.01 0.398 0.197 0.802 
 
      Insurance 
     1.Uninsured 0.1416 0.898 0.777 1.037 
 2.Private Insurance <.0001 0.7 0.625 0.783 unknown insurance 
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3.Medicaid 0.0007 0.792 0.693 0.906 
 4.Medicare <.0001 0.79 0.712 0.877 
 
      Tobacco 
     1.Never used <.0001 1.254 1.152 1.364 unknown 
2.Tobacco user <.0001 1.136 1.07 1.206 
  
Appalachia 
Table 5 is Hazard ratio for Appalachia. In this analysis the significant variables are 
sex (p<.0001), Stage (p<.0001), treatment (p<.0001), insurance (p<.0001) and tobacco 
(p<.0001). 
The hazard ratio (HR) observation shows that female has 1.16 (95%CI, 1.1-1.23) 
higher risk than male (p<.0001). With respect to age group ≥ 80 was 0.57 (95%CI, 0.49-
0.66), 0.6 (95%CI, 0.55-0.69), 0.73 (95%CI, 0.66-0.81), 0.79 (95%CI, 0.72-0.87) for age 
group 40-49 (p<.0001), 50-59 (p<.0001), 60-69 (p<.0001), and 70-79 (p<.0001) 
respectively. 
Stage level gradually increases the mortality risk  and the HR estimates were 0.87 
(95%CI, 0.39-1.9), 0.8 (95%CI, 0.7-0.9), 1.03 (95%CI, 0.88-1.19), 1.31 (95%CI, 1.18-
1.44), and 2.3 (95%CI, 2.1-2.5) for Stage 0 (p=0.73), Stage I (p=.0005), Stage II (p=0.6), 
Stage III (p<.0001), and Stage IV (p<.0001) relative to Unknown Stage, respectively. 
The No treatment group has 0.9 (95%CI, 0.47-1.75) a higher risk of mortality 
compared to Unknown/Other Therapy (p=0.7). The rest of the treatment groups were 0.29  
(95%CI, 0.15-0.57), 0.67 (95%CI, 0.34-1.3), 0.46 (95%CI, 0.4-0.89), 0.29 (95%CI, 0.14-
0.57), 0.37 (95%CI, 0.19-0.75), 0.4 (95%CI, 0.2-0.8), and 0.32 (95%CI, 0.16-0.6) for 
Surgery Only (p=.0003), Radiation Only (p=0.24), Surgery+Chemotherapy (p=0.02), 
Surgery+Radiation (p=.0004), Surgery+Radiation+Chemotherapy (p=.005), 
45 
 
Radiation+Chemotherapy (p=0.01), and chemotherapy (p=0.001) relative to Unknown 
Treatment, respectively. 
Uninsured group has 0.9 (95%CI, 0.74-1.1) higher risk compared to Unknown 
Insurance group (p=0.35). The HR estimates were 0.7 (95%CI, 0.6-0.8), 0.9 (95%CI, 
0.78-1.07), 0.79 (95%CI, 0.69-0.9) for Private Insurance (p<.0001), Medicaid (p=0.2), and 
Medicare (p=.001) relative to Unknown Insurance group. Both Never Use and Tobacco 
User groups increase the risk of mortality with an HR estimate 1.25 (95%CI, 1.15-1.36) 
and 1.13 (95%CI, 1.07-1.2) compared to Unknown User (p<.0001), respectively. 
 
Table 5. Hazard Ratio for Appalachia 
Varibale p 
Hazard 
Ratio 
95% Hazard Ratio 
Limits Reference 
Sex 
     1.Female <.0001 1.165 1.103 1.231 Male 
 
    
 Age     
 1.40-49 <.0001 0.572 0.492 0.666 
 2.50-59 <.0001 0.619 0.551 0.696 ≥80 
3.60-69 <.0001 0.737 0.669 0.812 
 4.70-79 <.0001 0.794 0.722 0.874 
 
      Stage 
     1.Stage I 0.0005 0.822 0.735 0.919 
 2.Stage II 0.6609 1.034 0.891 1.199 
 
3.Stage III 
<.0001 1.31 1.186 1.446 unknown Stage 
group 
4.Stage IV <.0001 2.312 2.104 2.54 
 5.Stage 0 0.7387 0.872 0.39 1.951 
 
      Treatment 
     1. No treatment 0.7797 0.911 0.472 1.755 
 2. Surgery Only 0.0003 0.294 0.152 0.57 
 3. Radiation Only 0.2429 0.675 0.349 1.306 
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4. Surgery + Chemotherapy 
0.0218 0.462 0.239 0.894 unknown/other 
therapy 
5. Surgery+Radiation 0.0004 0.293 0.149 0.576 
 6.Surgery+Radiation+Chemo 
therapy 
0.0055 0.378 0.19 0.751 
 7. Radiation+Chemotherapy 0.0117 0.429 0.222 0.828 
 8. Chemotherapy 0.0012 0.328 0.168 0.643 
 
      Insurance 
     1.Uninsured 0.3507 0.91 0.746 1.11 
 
2.Private Insurance 
<.0001 0.702 0.603 0.817 unknown insurance 
group 
3.Medicaid 0.2974 0.921 0.788 1.075 
 4.Medicare 0.001 0.796 0.695 0.912 
 
      Tobacco 
     1.Never used <.0001 1.345 1.188 1.522 unknown group 
2.Tobacco user <.0001 1.222 1.12 1.334 
  
Analysis 3. Cox survival regression analysis interaction between insurance type 
and treatment. 
Cox survival regression analysis for interaction between the variable insurance and 
treatment was performed to expand the interpretation. Table 6 is compilation analysis of 
the HR interaction between insurance type and treatment in all populations. The Box Plot 
for HR interaction is presented with 95% Confidence Intervals. 
Uninsured group With Treatment Surgery+Radiation+Chemotherapy has a 2.1 
(95%CI, 0.5-13.8) higher risk compared to Unknown Insurance With Unknown Treatment. 
The HR interaction estimates between Uninsured With Treatment 
Surgery+Radiation+Chemotherapy is highest when compared to Other Treatment, while 
Uninsured With Treatment Surgery Only has the lowest HR at 0.57 (95%CI, 0.3-0.9). With 
respect to Unknown Insurance and Unknown Treatment, the rest of the HR interaction 
estimates were 0.9 (95%CI, 0.7-1.1), 1.4 (95%CI, 0.9-2.2), 0.9 (95%CI, 0.6-1.4), 0.7 
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(95%CI, 0.3-1.6), 0.9 (95%CI, 0.7-1.4), and 1.05 (95%CI, 0.3-4.4) for Uninsured With No 
treatment, Uninsured With Radiation Only, Uninsured With Surgery+Chemotherapy, 
Uninsured With Surgery+Radiation, Uninsured With Radiation+Chemotherapy, and 
Uninsured With Chemotherapy, respectively (figure.1). 
The Private Insurance group With treatment Surgery+Radiation+Chemotherapy 
has a 1.26 (95%CI, 0.3-7.7) higher risk compared to Unknown Insurance With Unknown 
Treatment. The HR interaction estimates between Private Insurance With Treatment 
Surgery+Radiation+Chemotherapy is the highest among the Other Treatments, while 
Private Insurance With Treatment Surgery Only had the lowest HR at 0.56 (95%CI, 0.3-
0.8). With respect to Unknown Insurance and Unknown Treatment, the rest of the HR 
interaction estimates were 0.58 (95%CI, 0.6-0.7), 0.77 (95%CI, 0.5-1.1), 0.8 (95%CI, 0.5-
1.1), 0.7 (95%CI, 0.4-1.4), 0.8 (95%CI, 0.6-1.1), and 1.01 (95%CI, 0.3-4.09) for Private 
Insurance With No treatment, Private Insurance With Radiation Only, Private Insurance 
With Surgery+Chemotherapy, Private Insurance With Surgery+Radiation, Private 
Insurance With Radiation+Chemotherapy, and Uninsured With Chemotherapy, 
respectively (figure.2). 
Medicaid group With Treatment Surgery+Radiation+Chemotherapy has a 1.59 
(95%CI, 0.47-9.9) higher risk compared to Unknown Insurance with Unknown Treatment. 
The HR interaction estimates between Medicaid With Treatment 
Surgery+Radiation+Chemotherapy is the highest among Other Treatment while Medicaid 
With Treatment Surgery Only has the lowest HR with 0.64 (95%CI, 0.4-0.9). With respect 
to Unknown Insurance and Unknown Treatment the rest of the HR interaction estimates 
was 0.8 (95%CI, 0.7-0.9), 0.8 (95%CI, 0.5-1.4), 0.96 (95%CI, 0.6-1.3), 0.9 (95%CI, 0.4-
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1.94), 1.01 (95%CI, 0.7-1.4), and 0.9 (95%CI, 0.3-4.1) for Medicaid With No treatment, 
Medicaid With Radiation Only, Medicaid With Surgery+Chemotherapy, Medicaid With 
Surgery+Radiation, Medicaid With Radiation+Chemotherapy, and Medicaid With 
Chemotherapy, respectively (figure. 3). 
Medicare with Treatment Surgery+RadiationChemotherapy group has a1.74 
(95%CI, 0.5-10.5) higher risk compared to Unknown Insurance with Unknown Treatment. 
The HR interaction estimates between Medicare With Treatment 
Surgery+Radiation+Chemotherapy is the highest among Other Treatment, while 
Medicare With Treatment Surgery Only has the lowest HR at 0.66 (95%CI, 0.4-0.9). With 
respect to Unknown Insurance and Unknown Treatment, the rest of HR interaction 
estimates was 0.79 (95%CI, 0.7-0.8), 0.79 (95%CI, 0.5-1.2), 0.92 (95%CI, 0.6-1.2), 0.71 
(95%CI, 0.4-1.4), 0.85 (95%CI, 0.6-1.1), and 1.02 (95%CI, 0.39-4.1) for Medicare With 
No treatment, Medicare With Surgery Only, Medicare With Radiation Only, Medicare With 
Surgery+ Chemotherapy, Medicare With Surgery+ Radiation, Medicare With Radiation+ 
Chemotherapy, and Medicare With Chemotherapy, respectively (Figure.4). 
 
 
 
 
 
 
49 
 
Table.6 Hazard Ratio Interaction between Health Insurance and Treatment  
Treatment uninsured private insurance Medicaid Medicare 
P 
Value reference 
All Population Hazard 
Ratio 95% CI 
Hazard 
Ratio 95% CI 
Hazard 
Ratio 95% CI 
Hazard 
Ratio 95% CI 
 
1. No treatment 
0.9 0.7 1.1 0.58 0.5 0.6 0.8 0.7 0.9 0.79 0.7 0.8  insurance : unknown 
insurance 
2. Surgery Only 
0.57 0.3 0.9 0.56 0.3 0.8 0.64 0.4 0.9 0.66 0.4 0.9  treatment : unknown 
/other therapy 
3. Radiation Only 1.4 0.9 2.2 0.77 0.5 1.1 0.8 0.5 1.4 0.79 0.5 1.2  
 4. Surgery + 
Chemotherapy 
0.9 0.6 1.4 0.8 0.5 1.1 0.96 0.6 1.3 0.92 0.6 1.2 <.000
1 
 
5. Surgery+Radiation 
0.7 0.3 1.6 0.7 0.4 1.4 0.9 0.4 1.9
41 
0.71 0.4 1.4  
 6.Surgery+Radiation+C
hemotherapy 
2.1 0.5 13.
8 
1.26 0.3 7.7 1.59 0.4
71 
9.9
3 
1.74 0.5 10.
5 
 
 7.Radiation+Chemo 
Therapy 
0.9 0.7 1.4 0.8 0.6 1.1 1.01 0.7 1.4
11 
0.85 0.6 1.1  
 
8. Chemotherapy 
1.05 0.3
57 
4.5
09 
1.01 0.3
86 
4.0
97 
0.9 0.3 4.1
17 
1.02 0.3
93 
4.1
59 
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Figure 1. Hazard ratio interaction between uninsured and treatment 
 
 
Figure 2. Hazard ratio interaction between private insurance and treatment 
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Figure 3. Hazard ratio interaction between Medicaid and treatment 
 
 
                Figure 4. Hazard ratio interaction between Medicare and treatment 
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Analysis 4. Kaplan Meier survival trend analysis. 
The Kaplan Meier Survival Trend analysis was estimated for each of the significant 
variables.  Survival Trend for the interaction between insurance type and treatment was 
performed. Median survival time is presented in Table 7 and the product limit survival 
estimates curves. 
Kaplan Meier Estimate for All population 
The total sample for All Population is 49,512 patients with 66.51% censored (failed: 
16582, censored: 32930). Table 7 presents the Kaplan Meier median survival time for All 
Population stratified by significant variables. Kaplan-Meier estimates were significant for 
sex (p<.0001), race (p=0.04), age (p<.0001), Stage (p<.0001), insurance (p<.0001), 
treatment (p<.0001), county (p<.0001) and tobacco (p<.0001). Over all, the median 
survival time for All Population is 3.8 years (95%CI, 3.7-3.9). 
Median survival time stratified by sex was 3.4 years (95%CI, 3.2-3.6) for female 
and 4.3 years (95%CI, 4.1-4.4) for male. Stratified by race was 3.8 years (95%CI, 3.7-
3.9) for white and 4.2 years (95%CI, 3.7-4.7) for other. Median survival time stratified by 
age group gradually declined for older age groups (see figure.7). The median survival 
was 5 years (95%CI, 4.3-5.6), 4.9 years (95%CI, 4.5-5.2), 4.3 years (95%CI, 4.1-4.5), 3.4 
years (95%CI, 3.2-3.6), 2.2 (95%CI, 2-2.4) for age group 40-49, age group 50-59, age 
group 60-69, age group 70-79, and age group ≥80, respectively. 
As the Stage level became more advanced, median survival time gradually 
declined (see figure 8). The median survival time was 7.3 years (95%CI, 3.2-10.4), 7.3 
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years (7-7.5), 6.4 years (95%CI, 5.6-7), 3.4 years (95%CI, 3.2-3.6), 1.4 years (95%CI, 
1.4-1.5), 3.2 years (95%CI, 2.9-3.5) for Stage 0, Stage II, Stage III, Stage IV, and 
Unknown,respectively.  Figure 10 demonstrates that the longest median survival time 
stratified by treatment was 10.4 years (95%CI, 9.4-11.5) for 
Surgery+Radiation+Chemotherapy, while the shortest median survival time was 6.1 
years (95%CI, 5.7-6.5) for Treatment Surgery+Radiation. The median survival times for 
the rest were 8.1 years (95%CI, 7.6-8.6), 7.3 years (95%CI, 7.1-7.5), 6.4 years (95%CI, 
5.4-6.9), 7.4 years (95%CI, 6.5-8.3), 7.4 years (95%CI, 6.9-7.8), 7.3 years (95%CI, 6.6-
7.7), 6.8 years (95%CI, 4.8-8.8) for No treatment, Surgery Only, Radiation Only, 
Surgery+Chemotherapy, Surgery+Radiation, Radiation+Chemotherapy, Chemotherapy, 
and Unknown, respectively. 
The median survival times stratified by insurance were 3.1 years (95%CI, 2.5-3.8), 
5.4 years (95%CI, 5.1-5.7), 3.8 years (95%CI, 3.3-4.1), 3.5 years (95%CI, 3.4-3.6), and 
1.6 years (95% CI, 1.3-1.9) for Uninsured, Private Insurance, Medicaid, Medicare, and 
Unknown, respectively. The median survival times stratified by county did not yield 
significantly differences with 3.9 years (95%CI, 3.8-4.1) for Non-Appalachia and 3.4 years 
(95%CI, 3.2-3.7) for Appalachia. Both Never Use and Tobacco use  contribute to a decline 
median survival time with 3.2 years (95%CI, 2.8-3.4) for Never Use and 3.7 years (95%, 
3.6-3.9) for Tobacco Use, while the Unknown group alters the median survival time at 5 
years (95%CI, 4.5-5.3), (see figure. 11). 
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Table 7. Kaplan Meier Median Survival Time for All population 
Variable Median 95% CI 
Sex 
   1.Female 3.4 3.2 3.6 
2.Male 4.3 4.1 4.4 
Race 
   1.White 3.8 3.7 3.9 
2.Other 4.2 3.7 4.7 
Age 
   1.40-49 5 4.3 5.6 
2.50-59 4.9 4.5 5.2 
3.60-69 4.3 4.1 4.5 
4.70-79 3.4 3.2 3.6 
5.≥80 2.23 2 2.4 
Stage 
   1.Stage I 7.3 7 7.5 
2.Stage II 6.4 5.6 7 
3.Stage III 3.4 3.2 3.6 
4.Stage IV 1.4 1.4 1.5 
5.Stage 0 7.3 3.2 10.4 
6.unknown 3.2 2.9 3.5 
Treatment 
   1. No treatment 8.1 7.6 8.6 
2. Surgery Only 7.3 7.1 7.5 
3. Radiation Only 6.4 5.4 6.9 
4. Surgery +  Chemotherapy 7.4 6.5 8.3 
5. Surgery+Radiation 6.1 5.7 6.5 
6. Surgery+Radiation+Chemotherapy 10.4 9.4 11.5 
7. Radiation+Chemotherapy 7.4 6.9 7.8 
8. Chemotherapy 7.3 6.63 7.7 
9.unknown/other therapy 6.8 4.8 8.8 
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Insurance 
   1.Uninsured 3.1 2.5 3.8 
2.Private Insured 5.4 5.1 5.7 
3.Medicaid 3.8 3.3 4.1 
4.Medicare 3.5 3.4 3.6 
5.unknown 1.6 1.3 1.9 
County 
   1.Non Appalachia 3.9 3.87 4.14 
2.Appalachia 3.4 3.2 3.7 
Tobacco 
   1.Never used 3.2 2.8 3.4 
2.Tobacco user 3.7 3.6 3.9 
3.unknown 5 4.5 5.3 
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          Figure 5: Kaplan Meier survival curves based on sex for All Population                                 Figure 6: Kaplan Meier survival curves based on race for all population 
          
                                     
         Figure 7: Kaplan Meier survival curves based on Age for all population                                Figure 8: Kaplan Meier survival curves based on Stage for all population                            
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         Figure 11: Kaplan Meier survival curves based on Tobacco for all population       Figure 12: Kaplan Meier survival curves based on County for all population 
Figure 9: Kaplan Meier survival curve based on Insurance for all 
population. 
Figure 10: Kaplan Meier survival curve based on Treatment for 
all population. 
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Kaplan Meier Estimate for Non-Appalachia 
Total sample for Non-Appalachia is 33495 patients with 66.3% censored (failed: 
11288, censored: 22207). Kaplan Meier median survival times for Non-Appalachia 
stratified by significant variables are presented in Table 8. Kaplan-Meier estimates were 
significant for sex (p<.0001), race (p=0.05), age (p<.0001), Stage (p<.0001), insurance 
(p<.0001), treatment (p<.0001), and tobacco (p<.0001). Over all, the median survival time 
for Non-Appalachia is 3.9 years (95%CI, 3.8-4.1). 
Median survival time stratified by sex was 3.6 years (95%CI, 3.4-3.6) for female 
and 4.4 years (95%CI, 4.2-4.6) for male; Stratified by race, 3.9 years (95%CI, 3.8-4.1) for 
white and 4.3 years (95%CI, 3.8-6.5) for other; Stratified by age group demonstrated a 
gradual decline for older age groups with the exception of age group 40-49 and age group 
50-59 (figure.15). The median survival was 4.9 years (95%CI, 4.4-5.9), 5 years (95%CI, 
4.7-5.5), 4.5 years (95%CI, 4.3-4.9), 3.5 years (95%CI, 3.3-3.7), 2.4 (95%C, 2.2-2.6) for 
age group 40-49, age group 50-59, age group 60-69, age group 70-79, and age group 
≥80, respectively. 
As shown in All Population, for Non-Appalachia as the Stage level become more 
advanced, median survival time gradually declined (see figure.18). The median survival 
time was 7.3 years (95%CI, 3.2-12), 7.5 years (7.2-7.9), 6.5 years (95%CI, 5.7-7.2), 3.5 
years (95%CI, 3.3-3.8), 1.4 years (95%CI, 1.36-1.5), 3.2 years (95%CI, 2.8-3.7) for Stage 
0, Stage II, Stage III, Stage IV, and Unknown,respectively.  Figure 26 shows the longest 
median survival time stratified by treatment was 8.4 years (95%CI, 9.4-11.5) for Surgery 
Only while the shortest median survival time was 1.8 years (95%CI, 5.7-6.5) for Treatment 
Surgery+ Chemotherapy. The rest of the median survival times were  1.5 years (95%CI, 
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1.3-1.6), 2.2 years (95%CI, 2.2-2.5), 7.3 years (95%CI, 6.7-8), 6.8 years (95%CI, 5.3-
7.8), 3 years (95%CI, 2.7-3.2), 6.5 years (95%CI, 5.7-7.4), 0 years (95%CI, 0-0.26) for 
No treatment, Radiation Only, Surgery+Radiation, Surgery+Radiation+ Chemotherapy, 
Radiation+Chemotherapy, Chemotherapy, and Unknown, respectively. 
The median survival time stratified by insurance was 3.3 years (95%CI, 2.5-3.8), 
5.4 years (95%CI, 5.1-5.9), 4.1 years (95%CI, 3.6-4.9), 3.6 years (95%CI, 3.5-3.8), and 
1.5 years (95% CI, 1.2-1.8) for Uninsured, Private Insurance, Medicaid, Medicare, and 
Unknown, respectively. As for tobacco use both Never Use and Tobacco Use contribute 
to a decline in the median survival time of 3.2 years (95%CI, 2.9-3.6) for Never Use and 
3.9 years (95%, 3.8-4.1) for Tobacco Use, while the Unknown group altered the median 
survival time at 4.9 years (95%CI, 4.6-5.4), (see figure. 19). 
Table 8. Kaplan Meier Median Survival Time Non Appalachia 
 
    Variable Median 95% CI 
    Sex 
   1.Female 3.6 3.4 3.8 
2.Male 4.4 4.2 4.6 
 
 
  Race 
   1.White 3.9 3.8 4.1 
2.Other 4.3 3.8 6.5 
    Age 
   1.40-49 4.9 4.4 5.9 
2.50-59 5 4.7 5.5 
3.60-69 4.5 4.3 4.9 
4.70-79 3.5 3.3 3.7 
5.≥80 2.4 2.2 2.6 
 
 
  Stage 
   1.Stage I 7.5 7.2 7.9 
2.Stage II 6.5 5.7 7.2 
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3.Stage III 3.5 3.3 3.8 
4.Stage IV 1.4 1.36 1.5 
5.Stage 0 7.3 3.2 12 
6.unknown 3.2 2.8 3.7 
 
  
 Treatment 
   1. No treatment 1.5 1.3 1.6 
2. Surgery Only 8.4 8.2 8.8 
3. Radiation Only 2.27 2.02 2.5 
4. Surgery +  Chemotherapy 1.8 1.7 2 
5. Surgery+Radiation 7.3 6.7 8 
6. Surgery+Radiation+Chemotherapy 6.8 5.3 7.8 
7. Radiation+Chemotherapy 3 2.7 3.2 
8. Chemotherapy 6.5 5.7 7.4 
9.unknown/other therapy . . 0.26 
    Insurance 
   1.Uninsured 3.3 2.5 3.8 
2.Private Insured 5.4 5.1 5.9 
3.Medicaid 4.14 3.6 4.9 
4.Medicare 3.6 3.5 3.8 
5.unknown 1.5 1.2 1.8 
 
   
Tobacco 
   1.Never used 3.2 2.9 3.6 
2.Tobacco user 3.9 3.8 4.14 
3.unknown 4.9 4.6 5.4 
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                                     Figure 14: Kaplan Meier survival curve based on Race for Non-Appalachia 
   
                                               
       Figure 15: Kaplan Meier survival curve based on Age for Non-Appalachia                            Figure 16: Kaplan Meier survival curve based on Stage for Non-Appalachia 
Figure 13: Kaplan Meier survival curve based on Sex for Non-
Appalachia 
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       Figure 17: Kaplan Meier Survival based on Insurance for Non-Appalachia 
                                
          
                                                                                 
                                                                                             Figure 19: Kaplan Meier survival based on Tobacco for Non-Appalachia 
Figure 18: Kaplan Meier survival based on Treatment for Non-
Appalachia 
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Kaplan Meier Estimate for Appalachia 
The total sample for Appalachia is 16017 patients with 66.9% censored (failed: 
5294, censored: 10723).The Kaplan Meier median survival time for Appalachia stratified 
by significant variables is shown in Table 9. Kaplan-Meier estimates were significant for 
sex (p<.0001), age (p<.0001), Stage (p<.0001), insurance (p<.0001), treatment 
(p<.0001), and tobacco (p<.0001), but not significant for race (p=0.13). Over all, the 
median survival time for Appalachia was 3.4 years (95%CI, 3.2-3.7). 
Median survival time stratified by sex was 3.1 years (95%CI, 2.9-3.3) for female 
and 3.9 years (95%CI, 3.7-4.3) for male. Median survival time stratified by age group 
gradually declined for the older age groups (figure.29). The median survival was 5.2 years 
(95%CI, 3.3-7.1), 4.4 years (95%CI, 3.9-5), 3.6 years (95%CI, 3.4-4), 3.2 years (95%CI, 
2.8-3.5), 1.7 (95%C, 1.5-1.8) for Age Group 40-49, Age Group 50-59, Age Group 60-69, 
Age Group 70-79, and Age Group ≥80, respectively. 
Unlike in All population and Non-Appalachia, the median survival time gradually 
declined from Stage I and above (see figure.21). The median survival time was 4.5 years 
(95%CI, 1.4-10.4), 6.7 years (6.1-7.1), 5.8 years (95%CI, 5.1-7.5), 3.2 years (95%CI, 2.8-
3.4), 1.3 years (95%CI, 1.2-1.4), 3.2 years (95%CI, 2.8-3.8) for Stage 0, Stage II, Stage 
III, Stage IV, and Unknown,respectively.  Figure 23 demonstrates that the longest median 
survival time stratified by treatment was 7.7 years (95%CI, 7.2-8.5) for Surgery Only, 
while the shortest median survival time was 1.9 years (95%CI, 1.7-2.2) for Treatment 
Surgery+ Chemotherapy. The rest of the median survival times were  1.4 years (95%CI, 
1.3-1.5), 2.2 years (95%CI, 1.8-2.5), 5.9 years (95%CI, 5.3-7), 4.5 years (95%CI, 3.1-
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7.3), 2.7 years (95%CI, 2.5-2.9), 5.8 years (95%CI, 4.1-7), 2.1 years (95%CI, 0.5-2.1) for 
No treatment, Radiation Only, Surgery+Radiation, Surgery+Radiation+Chemotherapy, 
Radiation+Chemotherapy, Chemotherapy, and Unknown, respectively. 
The median survival time stratified by insurance was 2.8 years (95%CI, 2-5.07), 
5.2 years (95%CI, 4.4-5.8), 3.2 years (95%CI, 2.8-3.8), 3.2 years (95%CI, 3.03-3.4), and 
1.8 years (95% CI, 1.2-1.8) for Uninsured, Private Insurance, Medicaid, Medicare, and 
Unknown, respectively. As for tobacco use both Never Use and Tobacco Use contribute 
to a decline in median survival time with 2.9 years (95%CI, 2.4-3.5) for Never Use and 
3.3 years (95%, 3.1-3.5) for Tobacco Use, while Unknown alters the median survival time 
with 4.7 years (95%CI, 3.8-5.5), (see figure. 25). 
Table 9. Kaplan Meier Median Survival Time for Appalachia 
 
    Variable Median 95% CI 
    Sex 
   1. Female 3.1 2.9 3.3 
2. Male 3.9 3.7 4.3 
    Age 
   1. 40-49 5.2 3.3 7.1 
2. 50-59 4.4 3.9 5 
3. 60-69 3.6 3.4 4 
4. 70-79 3.2 2.8 3.5 
5. ≥80 1.7 1.5 1.8 
    Stage 
   1. Stage I 6.7 6.1 7.1 
2. Stage II 5.8 5.1 7.5 
3. Stage III 3.2 2.8 3.4 
4. Stage IV 1.3 1.2 1.4 
5. Stage 0 4.5 1.4 10.4 
6. Unknown 3.2 2.8 3.8 
    Treatment 
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1. No treatment 1.4 1.3 1.5 
2. Surgery Only 7.7 7.2 8.5 
3. Radiation Only 2.2 1.8 2.5 
4. Surgery + Chemotherapy 1.9 1.7 2.2 
5. Surgery+Radiation 5.9 5.3 7 
6. Surgery+Radiation+Chemotherapy 4.5 3.1 7.3 
7. Radiation+Chemotherapy 2.7 2.5 2.9 
8. Chemotherapy 5.8 4.1 7 
9.unknown/other therapy 2.1 0.5 2.1 
    Insurance 
   1. Uninsured 2.8 2 5.07 
2. Private Insured 5.2 4.4 5.8 
3.Medicaid 3.2 2.8 3.8 
4. Medicare 3.2 3.03 3.4 
5. Unknown 1.8 1.3 3.05 
    Tobacco 
   1.Never used 2.9 2.4 3.5 
2.Tobacco user 3.35 3.17 3.5 
3.unknown 4.7 3.8 5.5 
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   Figure 20: Kaplan Meier survival curve based on Sex for Appalachia                                      Figure 11: Kaplan Meier survival curve based on Age for Appalachia 
                                                                                                                                                                                                            
 
Figure 22: Kaplan Meier survival curve based on Stage for Appalachia 
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Figure 23: Kaplan Meier survival curve based on Treatment for Appalachia                                          Figure 24: Kaplan Meier survival curve based on Insurance for Appalachia 
 
 
Figure 25: Kaplan Meier survival curve based on Tobacco for Appalachia
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Kaplan Meier Estimate for interaction between Insurance and Treatment 
A Kaplan Meier estimate for interaction between the insurance and treatment 
variables was performed to estimate the survival time based on the interaction between 
insurance and treatment. The median survival time of the interaction between insurance 
and treatment is presented in Table 10. The median and 95%confidence interval are 
presented in the boxplot graph. 
The longest median survival time for the uninsured group is the uninsured 
population that receives treatment for Surgery+Radiation+Chemotherapy at 10.89 years 
(95% CI, 0.7-12.9), while the shortest median survival time occurs in the  uninsured 
population that receives No treatment at 0.8 years (95%CI, 0.4-1.9). The rest of the 
median survival times estimate was 1.07 (95%CI, 0.74-1.64), 9.5 years (95%CI, 6.6-
11.8), 1.9 years (95% CI, 1.6-2.4), 7.3 years (95%CI, 5.2-11.47), 6 years (95%CI, 3.5-.) 
for Uninsured With No treatment, Uninsured With Surgery Only, Uninsured With 
Surgery+chemotherapy, Uninsured With Surgery+Radiation, Uninsured With 
Radiation+Chemotherapy, and uninsured with chemotherapy, respectively (figure.26). 
There is no observation for Uninsured With Unknown/Other Therapy. Interaction for 
uninsured and chemotherapy does not yield a value for the upper limit of 95% confidence 
interval. 
Private insurance population who receive Treatment Surgery Only had the longest 
median survival time at 9.5 years (95%CI, 8.9-10.2), while those who received Treatment 
Surgery+Chemotherapy had the shortest median survival time at 2.09 years (95% CI, 
1.8-2.3). For the remainder the median survival time estimate was 2.2 years (95%CI, 1.6-
2.6), 2.3 years (95%CI, 1.8-2.8), 7.3 years (95%CI, 6.8-7.8), 7.9 years (95%CI, 5.6-9.9), 
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3.2 years (95%CI, 2.9-3.6), and 6.9 years (95% CI, 5.6-8.1) for Private Insurance With 
No treatment, Private Insurance With Radiation Only, Private Insurance With 
Surgery+Radiation, Private Insurance With Surgery+Radiation+Chemotherapy, Private 
Insurance With Surgery+Radiation, and Private Insurance with Chemotherapy, 
respectively (figure.27). There was no observation for Private Insurance and 
Unknown/Other Therapy. 
The Medicaid population receiving Treatment Surgery Only had the longest 
median survival time at 8.6 years (95%CI, 7.7-10.4), while those who received No 
treatment had the shortest median survival time at 1.6 years (95% CI, 1.3-2.07). The 
median survival time estimates of the remainder were 2.3 years (95%CI, 1.6-3.1), 1.9 
years (95%CI, 1.5-2.6), 5.6 years (95%CI, 4-.), 7.3 years (95%CI, 4.5-12.6), 2.5 years 
(95%CI, 2-3.4), and 6.7 years (95% CI, 4.8-.) for Medicaid with Radiation Only, Medicaid 
With Surgery+Chemotherapy, Medicaid With Surgery+Radiation, Medicaid With 
Surgery+Radiation +Chemotherapy, Medicaid With Radiation+Chemotherapy, Medicaid 
With Chemotherapy, respectively (figure.28). Medicaid with Unknown/Other Therapy had 
a 2 year median survival time; however, there were not enough observations to calculate 
the 95% confidence interval. Some observation did not have a large enough sample size 
to calculate the upper limit of the 95% confidence interval. 
The Medicare population receiving Treatment Surgery Only had the longest 
median survival time at 7.7 years (95%CI, 7.3-8), while those receiving Unknown/Other 
Therapy had the shortest median survival time at 0.5 years (95% CI, 0.2-.). The median 
survival time estimate for the remainder was 1.4 years (95%CI, 1.3-1.5), 2.3 years 
(95%CI, 2.5-.), 1.7 years (95%CI, 1.6-1.9), 7.1 years (95%CI,5.7-8), 5.3 years (95%CI, 4-
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5.9), and 2.8 years (95% CI, 2.6-3), 5.7 years (95%CI, 4.9-6.5) for Medicare With No 
treatment, Medicare With Radiation Only, Medicare With Surgery+Chemotherapy, 
Medicare With Surgery+Radiation, Medicare With Surgery+Radiation +Chemotherapy, 
Medicare With Radiation+Chemotherapy, Medicare With Chemotherapy, respectively 
(figure.29).  
Over all, the unknown insurance group yielded no  median survival times although 
the  lower limit of the 95% confidence interval for both was less than one year for 
interaction with Treatment Radiation Only (0.5 years) and 
Surgery+Radiation+Chemotherapy (0.8 years), respectively. No observations were 
available for interaction between Unknown Insurance with Unknown/Other Therapy. The 
remaining median survival time estimates were 1.12 years (95%CI, 1-1.5), 5.5 years 
(95%CI, 3.6-.), 0.5 years (95%CI, 0.2-.), 5.29 years (95%CI, 4.27-.), and 3 years (95%CI, 
1.6-5.3) for Unknown Insurance With No treatment, Unknown Insurance With Surgery 
Only, Unknown Insurance With Surgery+Chemotherapy, Unknown Insurance With 
Surgery+Radiation, and Unknown Insurance With Radiation+Chemotherapy, respectively 
(figure. 30). Some observations did not have a large enough sample size to calculate the 
upper limit of the 95% confidence interval. 
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Table 10. Kaplan Meier Median time survival interaction between insurance and treatment  
Treatment 
uninsured private insured Medicaid Medicare unknown 
median 95% CI median 95% CI median 95% CI median 95% CI median 95% CI 
1. No treatment 1.07 0.74 1.64 2.2 1.64 2.6 1.6 1.3 2.07 1.4 1.3 1.5 1.12 1 1.5 
2. Surgery Only 9.5 6.6 11.8 9.5 8.9 10.2 8.6 7.7 10.4 7.7 7.3 8 5.5 3.6 . 
3. Radiation Only 0.8 0.4 1.9 2.3 1.8 2.8 2.3 1.6 3.1 2.3 2.03 2.5 . 0.5 . 
4. Surgery + Chemotherapy 1.9 1.6 2.4 2.09 1.8 2.3 1.9 1.5 2.6 1.7 1.6 1.9 0.5 0.2 . 
5. Surgery+Radiation 7.3 5.2 11.47 7.3 6.8 7.8 5.6 4 0 7.1 5.7 8 5.29 4.27 . 
6.Surgery+Radiation+Chemotherapy 10.89 0.7 12.9 7.9 5.6 9.9 7.3 4.5 12.6 5.3 4 5.9 . 0.8 . 
7. Radiation+Chemotherapy 2.5 2 3.6 3.2 2.9 3.6 2.5 2 3.4 2.8 2.6 3 3 1.6 5.3 
8. Chemotherapy 6 3.5 . 6.9 5.6 8.14 6.7 4.8 . 5.7 4.9 6.5 9.8 0.7 9.8 
9.unknown/other therapy . . . . . . 2 . . 0.5 0.2 . . . . 
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Figure 26:  Uninsured& Treatment median survival time all population 
 
 
                                                 Figure 27: Private ins& Treatment median survival time for all population 
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Figure 28: Medicaid& Treatment median survival time curve all population 
 
 
                                                    Figure 29: Medicare& Treatment median survival time for all population 
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Figure 30: Unknown & Treatment median survival time for all population 
    
                                    
            
C. Answer to Research Question. 
Question 1. Does the type of health insurance influence the modality 
of lung cancer treatment and survival benefit for medically underserved 
patients? 
 
In all treatment groups the largest proportion of the Kentucky population 
27.9% receiving No treatment lives in Non-Appalachia counties, while 34.2% of 
those living in Appalachia counties receive No treatment.  In Non-Appalachia 
(22.4%) and in Appalachia (21%) received Treatment Radiation+Chemotherapy, 
while the fewest received Treatment Surgery+Radiation +Chemotherapy in the 
Non-Appalachia groups (1.7%) and in the Appalachia group (1.5%). Most of the 
population in the cohort is in the Medicare population (64%), which is an older 
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population above 65 years of age and the most frequent Stage level found in this 
group is Stage IV (39%). Over all, the uninsured group has a higher mortality risk 
as compare with the insured population. On the other hand, enrollment in private 
insurance, Medicaid, and Medicare reduces the mortality risk for All Population and 
Non-Appalachia, but for Appalachia Medicaid demonstrates same high mortality 
risk as Uninsured.  
Question 2. Does the lung cancer treatment for a medically 
underserved population in Kentucky reflect disparities? 
Disparities are reflected in large number of lung cancer patients who do not 
receive treatment (see Tables 1 & 2). Although the hazard ratio between variables 
demonstrates a difference in the value, the pattern is similar for all observation 
groups (see Table 3 & 4). In the insurance group, the Private Insurance population 
had an increased opportunity to receive treatment for early Stage. Treatment 
combinations had a reciprocal result between frequency numbers and hazard ratio. 
For example Surgery+Radiation+Chemotherapy has proven to reduce the 
mortality risk, but it was the lowest treatment choice. In the All Population group, 
Treatment Surgery Only reduced the mortality risk significantly, while for Non-
Appalachia and Appalachia the mortality risk is lower when these groups receive 
Treatment Surgery Only and Treatment Surgery+Radiation (see Table 3, 4 & 5).  
The Kaplan Meier estimate for insurance type demonstrates Private Insurance 
demonstrates the longest survival time for all observation groups. As for treatment, 
Treatment Surgery Only and Surgery+Radiation+Chemotherapy demonstrate 
longer median survival times compared to Other Treatment (see Table 6, 7 & 8). 
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D. Discussion. 
This study demonstrated that most of the population suffering from lung 
cancer (NSCLC type) did not receive treatment and a large part of the population 
is found in advanced Stages of the disease. Despite age and Stage as strong 
predictors of survival, disparities in the recommended treatment for early Stage 
disease occurs between health insurance types. The general demographic 
description for this cohort are females seventy or more years of age;  while 
individuals who are white race and tobacco users with Stage IV disease 
predominantly live in Non-Appalachia counties. Race is not significant in terms of 
receiving recommended treatment for Non-Appalachia and Appalachia. This result 
compares with previous studies that found that there were no racial disparities in 
lung cancer for populations with the same access to medical care [2]. In this cohort 
female occurred  more frequently than male as the rate of new lung cancer cases 
for women has risen 98 percent over the past 37 years  [75]. The study 
demonstrated that there underutilization of lung cancer treatment occurred in 
Kentucky since 30 percent of the population do not receive treatment and most 
patients do not receive recommended treatment [23].  
Lung cancer treatment is varied and depends on the Stage of the disease. 
For patients with early Stage NSCLC, the best opportunity for cure remains 
surgical resection [61]. Unfortunately, health care insurance status often dictates 
whether or not an operation is performed [73]. The study found that most patients 
who were treated with surgery at an early Stage of the disease are patients with 
private insurance and Medicare residing in both Non-Appalachia and Appalachia. 
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A previous study reported that early Stage NSCLC patients with Medicare, 
Medicaid or no insurance were significantly less likely than patients with private 
insurance to undergo surgery [61, 73]. Most individuals undergoing treatment for 
lung cancer in Kentucky received a combination of radiation and chemotherapy, 
which is common for Stage III NSCLC.  However, frequently patients are found in 
Stage IV but large numbers of them receive treatment with 
Radiation+Chemotherapy instead of chemotherapy even though chemotherapy is 
the recommended treatment for Stage IV [20]. Combined modality therapy confers 
survival advantages on patients, but it is not always utilized in all patients [36]. 
Effective treatment for advanced Stages of lung cancer is a combination of 
therapies, but a good prognosis depends on the early detection of the cancer [7-
9]. This may reflect the increased access of radiotherapy and chemotherapy in 
rural areas and among referring physicians [36]. There are many factors involved 
in the choice of treatment including its financial feasibility regardless the Stage of 
the  cancer Stage [12]. Treatment often falls short of recommended care due to 
clinical reasons, including inoperable conditions, comorbid conditions, the patient’s 
refusal and advanced age [73]. Physicians may utilize  surgery as palliative 
treatment for Stage IV [76]. 
The financial feasibility is  an issue depending on the method of payment 
such as  out of pocket or a government insurance plan [17].The elder population 
was largest group in both  Non-Appalachia and Appalachia,  making them eligible 
for Medicare. Among insurance groups, private insurance demonstrated a better 
outcome for reducing mortality risk and increasing survival time. Unfortunately, not 
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all patients could afford to have a health plan other than Medicare or Medicaid. 
Patients with lung cancer without insurance do poorly because access to care is 
limited and they present with a more advanced Stage of disease that is less 
amenable to treatment [57]. However, patients with Medicare had much better 
outcomes when compared to the uninsured. Therefore, government insurance 
plans contribute to improving the wellbeing of the medically underserved [19]. This 
finding supports other studies that demonstrated that Medicare insured patients 
with NSCLC had superior survival overall [73]. 
Utilizing univariate and multivariate analysis, race was not associated with 
increased survival in Appalachia, but was significant for All Population and Non-
Appalachia. However, a strong trend pattern appears in the analysis as applied to 
all observation groups. The Hazard Ratio gradually increases for the older age 
groups as well as Stage with advanced Stages of the disease. For Insurance type, 
the uninsured patient has the highest mortality risk; private insurance has the 
lowest, while Medicaid and Medicare share almost the same value. For Treatment 
Choice, the highest mortality risk in all observation groups was treatment with 
Radiation Only.  Lung cancer is mostly a disease of the elderly and radiation is the 
recommended therapy [45]. In 2011, 82 percent of those living with lung cancer 
were 60 years of age or older [75]. Most lung cancer patients are diagnosed with 
advance Stage disease [27]. Elderly patients with advanced lung cancer Stages 
tend to be more physically fragile and cannot not withstand the side effects of more 
complicated treatment. Therefore, the treatment of choice for patients equal to or 
older than 80 years of age is radiation and this explains the increasing mortality 
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risk for single treatment Radiation Only in this cohort. This finding confirms prior 
studies that indicated that some physicians do not endorse aggressive therapy for 
elderly cancer patients, perhaps because they do not expect the gain in survival to 
outweigh the potential harm to patient morbidity and quality of life [20]. 
Lung cancer cannot be separated from its leading cause, smoking. Tobacco 
use contributes to the high prevalence of lung cancer in Kentucky. Approximately 
79 percent of the study population (with lung cancer) has use tobacco. (See 
table.1). Across all states, the prevalence of cigarette smoking among adults 
ranges from 9.3% to 26.5%, Kentucky ranks 49th among the states [77]. However, 
both the Never Used group and Tobacco User had high risk of mortality. Exposure 
to secondhand smoke causes approximately 7,330 lung cancer deaths among 
nonsmokers in US every year [78]. Nonsmokers have a 20-30 percent greater 
chance of the developing lung cancer if they are exposed to secondhand smoke 
at home or work [79].  
Over all, Uninsured, Private Insurance, Medicaid and Medicare patients 
whether they reside at Non-Appalachia or Appalachia have the opportunity to 
reduce their mortality risk if they receive early diagnosis and recommended 
treatment. On the contrary, mortality risk increases when the patients are older 
with advanced Stages for the disease, are uninsured, receive No treatment or 
receive ineffective treatment [15].  Different Stage of the disease and aging are 
important survival influences. For Medicaid and Medicare patients the opportunity 
to reduce mortality risk from lung cancer is better with any kind of treatment rather 
than No treatment since they often present with advanced Stage of the disease. 
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On the other hand, most patients with private insurance have a lower mortality risk 
and receive Treatment Surgery Only because the disease was found at an early 
Stage. Private insurance patients have a longer exposure to health care benefits 
that make them more aware with their health [14], while and the medically 
underserved were less likely to be appropriately staged and to receive 
recommended treatment [80]. Planned therapies, palliative care, and the 
management of cancer symptoms may be jeopardized by the loss of insurance 
[17]. Nevertheless, access to health insurance influences the amount and quality 
of health care received and thus the insurance status of cancer patients may be 
important to their survival [49]. There is also the possibility that patients tend to 
choose less effective treatments with lower cost [44].  
In this study the overall censored percentage is 66.51% with Non-
Appalachia (3.9 years) having a longer time of survival than Appalachia (3.4 
years). A previous study reported that in Kentucky only 2.5% of patients will survive 
5 years or more [27]. The five-year survival rate for lung cancer is 54.0 percent for 
cases detected when the disease is still localized (within the lungs). However, only 
15 percent of lung cancer cases are diagnosed at an early Stage. For distant 
tumors (spread to other organs) the five-year survival rate is only 4.0 percent [75]. 
An analysis of the Kaplan Meier estimate attempted to identify the survival 
outcome in lung cancer based on associated variables. In this cohort, male with 
other race has a longer survival time for all population and Non-Appalachia; 
however, race is not significantly associated with lung cancer survival for 
Appalachia. Survival time is decreasing as the patients get older and the disease 
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Stage becomes more advanced. Stage III median survival time decreases 
significantly approximately half of that for Stage II. This trend was seen in all three 
observation groups. When treatment is considered, a combination of surgery, 
radiation and chemotherapy demonstrated the longest survival time for All 
Population, but when broken down to Non-Appalachia and Appalachia Treatment 
Surgery Only showed the longest survival time. Many patients with early Stages of 
the disease, who live in Appalachia, may not receive the recommended treatment 
of Surgery Only. As their cancer approaches a higher Stage number of patients 
with advanced Stage disease increases. Rural Kentuckians value the services, 
convenience, and security that rural hospitals offer and usually they are not willing 
to pay more for specialized care that may be available in larger medical treatment 
centers [80]. Private insurance patients had longer survival times in all observation 
groups compared with other insurance types. Tobacco Use had a slightly longer 
survival time when compared to Never Use and Unknown use. In Kentucky, 25.2% 
of the adult population (aged 18+ years) — over 822,000 individuals—are currently 
cigarette smokers [77] . Although Non-Appalachia and Appalachia had same 
survival time based on variable predictors, overall survival time in Appalachia is 
less when compared to Non-Appalachia. 
The finding from Cox Survival Regression interaction between insurance 
type and treatment for all population showed that uninsured patients with a 
combination therapy of Surgery+Radiation+Chemotherapy has the highest 
mortality risk,  but uninsured with single therapy of Radiation or Chemotherapy  
had a higher mortality risk when compared to other therapy. Private insurance and 
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Medicare patients with combination therapy of Surgery+Radiation+Chemotherapy 
and single therapy of Chemotherapy had higher mortality risk when compared with 
other therapy. Medicaid patients with combination therapy of 
Surgery+Radiation+Chemotherapy and Radiation+Chemotherapy had a higher 
mortality risk when compare with other therapy. All insurance type has the lowest 
mortality risk on single therapy for Surgery Only.  
In addition to examining the Hazard Ratio from interaction between 
insurance and treatment, this study also assessed the survival time. The study 
showed that all insurance type groups had superior survival time when the patient 
received treatment with a combination therapy of Surgery +Radiation and 
Surgery+Radiation+Chemotherapy. All insurance types also had increased 
survival times when patients received a single therapy of Surgery Only and 
Chemotherapy Only. Over all, combination and single therapy that yield higher 
mortality risk is the recommended treatment for advanced Stages of the disease, 
while single therapy of Surgery Only is the recommendation treatment for early 
Stages. Early diagnosis and recommended treatment of lung cancer is important 
for improving survival [3, 9]. These results corroborate previous studies 
demonstrating that ensuring sufficient health insurance substantially increases the 
proportion of patients diagnosed at early Stage surviving [14].  
The purpose of this study is to determine the impact of health insurance 
policy on lung cancer treatment in the Commonwealth of Kentucky, especially for 
the medically underserved population. Medically underserved does not always 
mean those individuals who live in a rural county (Appalachia), but it also includes 
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those individuals who fall short in their quest of finding quality health care due to 
their personal limitations. Most findings of this study are relevant to other lung 
cancer studies, but we did not find obvious differences in the outcome between 
Non-Appalachia and Appalachia. The strongest predictors for lung cancer survival 
are age and Stage of cancer. Although patients with private insurance 
demonstrated better outcomes when compared to other health insurance types, 
this result did not affect the mortality risk and survival time when the cancer was 
already in an advanced Stage. However, having health insurance is better than not 
having assurance of obtaining recommended treatment. Apparently, insurance at 
some point enhances the patients’ efforts of obtaining standard treatment 
regardless their cancer Stage. On the other hand, the fact that there are large 
numbers of patients who do not get treatment and high percentage of censoring 
value indicate the poor initial condition of the patients. Medicaid enrollment policies 
that require individuals to meet disability requirements often place patients close 
to the end of life [19]. Being Uninsured or having Medicaid insurance results in a 
substantially increase in the risk of being diagnosed with more advanced states of 
disease than having privately insurance [14].  
Care for persons with advanced cancer is more intensive and costly than 
for early Stage and caries a higher risk for complications related to treatment [17]. 
On the contrary, the goal of delivering value care is what matters for patients and 
unites the interest of all actors in the system. If value improves, patients, payers, 
providers, and suppliers can all benefit, while the economic sustainability of the 
health care system increases [35]. The outcomes from Lung cancer treatment in 
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Kentucky are suboptimal, making it worthwhile for the decision maker to review the 
state’s health insurance coverage policies. As part of the Patient Protection and 
Affordable Care Act (ACA) of 2010, two new opportunities for health care coverage 
were established for many uninsured individuals. The first opportunity was based 
on Medicaid expansion where states had the opportunity to expand Medicaid 
coverage to individuals with household incomes up to 133% of the federal poverty 
level. The second opportunity was through the establishment of the Health 
Insurance Marketplace where individuals could purchase private health plans and 
potentially qualify for financial assistance while paying for their plans [81]. 
Screening programs for chronic disease like cancer part of the new plans based 
on the Affordable Care Act under section 4107 Title IV Prevention of Chronic 
Disease and Improving Public Health [82].  
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CHAPTER 5 
IMPLICATIONS FOR PUBLIC HEALTH 
 
A. Implications - and contributions 
 
 The value of US cancer care has been assessed through comparison to 
gains in survival time after a cancer diagnosis [53]. The Medicaid program is the 
nation’s health insurance safety net for economically disadvantaged individuals 
and disabled individuals including those who are diagnosed with cancer. Not only 
does Medicaid cover cancer care services for its enrollees, many uninsured low 
income persons turn to Medicaid when they are newly diagnosed with cancer [17]. 
However, the study demonstrates that most patients present initially with advanced 
Stage lung cancer, regardless of type of insurance. Therefore, from this study we 
understand that the expansion of lung cancer detection programs with health 
coverage for low income and uninsured individuals does not meet expectations. A 
notable finding is the outcome stagnancy based on the interaction between health 
insurance type and treatment. It demonstrates that it is imperative that the 
treatment process occur after early diagnosis and is associated with timely follow 
up.  
In addition to contributing to the lung cancer management literature, this 
study also develops baseline research for further investigation concerning lung 
cancer treatment based on new or additional health insurance policies. This study 
86 
 
provides evidence to policy makers to rapidly develop lung cancer management 
programs.  Health insurance based on the Affordable Care Act in addition to 
improved Medicare plans and expansion of Medicaid may contribute to improving 
treatment modalities in lung cancer. Screening programs endorsed by the 
Affordable Care Act should assist in the prevention of chronic disease. 
 
 
B. Recommendation 
 
Based on the Study findings two important recommendations are suggested: 
 
1. Despite the fact that Medicaid or Medicare cancer patients are better off 
than those not having insurance, insuring individuals at the level of 
screening programs will be less expensive  than enrolling these individuals 
when their prognosis is poor.  
2. It is important to address social and cultural factors that may limit access 
to cancer screening and early detection even for those with adequate 
insurance. 
C. Limitations 
 
There are number of important factors in the study that we are unable to assess 
with our data including socio-economic status, comorbidity data, hospital volume, 
treatment by multidisciplinary team, and pre-treatment staging. Another limitation 
is the possibility of insurance misclassification in elderly patients and lead time bias 
for the time patients enroll in Medicaid or Medicare. Suggestion for further research 
include considering survival rates in different time series and sensitivity testing for 
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initial treatment after screening and first diagnosis. The high percentage of 
censoring number in some observations also is a limitation making it difficult to 
develop estimations. 
 
D. Conclusions 
Over all, efforts in enhancing value care for lung cancer treatment is found in 
reducing disparities. Many studies demonstrate that lung cancer treatment has not 
been effective for several patient groups, most especially for those who are 
medically underserved. Treatment, even if it is provided to patients, will not 
improve survival for advanced Stage lung cancer patients [19].Changes in 
insurance coverage for the uninsured and underinsured need to consider the 
adequacy, availability and affordability of new programs. To achieve equity in 
healthcare, especially for individuals with cancer, these aspects need to be 
addressed in order to remove the barriers to disease screening and timely access 
to medical care providers [14]. The reasons behind the disparity in cancer care 
based on insurance status are likely multifactorial, including both the healthcare 
system and patient factors [61]. Much has yet to be learned in order to narrow the 
gap in the treatment and survival from lung cancer. Finally, improving patient 
outcomes by ensuring a more equitable dissemination of recommended therapies 
to all segments of population is one means for enhancing the value care in lung 
cancer. 
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APPENDIX X 
Appendix 1. Treatment Guidelines 
Treatment Guidelines for Non-Small Cell Lung Cancer 
Stage 0 Surgical resection 
Endoscopic surgery, laser therapy, electrosurgery, 
cryosurgery 
Stage IA Surgical resection Chemotherapy (adjuvant), radiation therapy 
Stage IB Surgical resection Chemotherapy (adjuvant), radiation therapy 
Stage 
IIA 
Surgical resection 
Chemotherapy (adjuvant), radiation therapy (primary or 
adjuvant) 
Stage 
IIB 
Surgical resection 
Chemotherapy (adjuvant), radiation therapy (primary or 
adjuvant) 
Stage 
IIIA 
Surgery then 
chemotherapy  
Chemotherapy and 
radiation 
Neoadjuvant chemotherapy and radiation 
Stage 
IIIB 
Chemotherapy and 
radiation 
  
Stage IV 
Chemotherapy  
Radiation therapy 
(palliative)  
Surgical resection 
(palliative) 
Combination therapy, internal radiation, targeted therapy, 
laser therapy 
Source : www.lung-cancer.com 
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